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INTRODUCTION    
 
Cervical cancer is the most common cancer in India and other developing countries. In 
India, it is the third largest cause of carcinoma mortality after carcinoma of oropharynx and 
esophagus. In India according to WHO report, the current estimates indicate 132000 new cases 
and 74000 deaths annually with an incidence of 23.5/1,00,000.(1) Thus India shares about one 
fourth of the global cervical cancer burden. The disease is preventable by screening, early 
diagnosis and treatment. Early stage cervical carcinoma can be treated with either radical 
hysterectomy or chemo radiation and both modalities of treatment have been accepted as equally 
effective in terms of survival and local control of the disease. 
 Radical hysterectomy consists of total removal of uterus including the parametrium, 
bilateral uterosacral ligaments and connective tissues nearby and it is accompanied by removal 
of pelvic lymph nodes. This surgical treatment is usually recommended in young women because 
it preserves ovarian function and vaginal pliability when compared to radiation therapy. It also 
provides additional information about pathological risk factors which affects survival outcome of 
the patients. This radical surgery is associated with various complications. The intra-operative 
complications are hemorrhage, injury to bladder, bowel, ureter and pelvic blood vessels. The 
immediate postoperative complications are urinary tract infection, wound dehiscence, 
thromboembolism, fistulas and lymphocyst formation. The late complications are bladder 
dysfunction, ureteral stenosis and lymphedema. 
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The 5 year survival rate depends upon the stage of the disease, histological type of the 
tumour and the presence or absence of pathological risk factors. The survival rate with early 
stage cervical carcinoma with radical hysterectomy and pelvic lymphadenectomy is nearly 90%. 
Retrospective studies in the literature have shown good survival outcome and minimal 
complications with proper case selection and good operative techniques. However 10-25% of 
patients will develop recurrence of the disease.  
The pathological risk factors which predict tumour recurrence are positive surgical 
margins, positive parametrium and positive lymph nodes. The 5 year survival rate of patients 
who have these high risk factors drops down to 40-55% if there is recurrence of disease. 
Adjuvant radiotherapy decreases the development of loco-regional recurrence with minimal 
effect on survival. Neoadjuvant chemotherapy is another alternative for patients with early stage 
cervical carcinoma with bulky tumour. The purpose of this study is to evaluate the survival 
outcome, complications and prognostic factors for recurrence of early stage cervical carcinoma 
patients treated with radical hysterectomy and pelvic lymphadenectomy in our hospital. 
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AIMS AND OBJECTIVES  
The aim of this study was to evaluate the survival outcome, complications and 
pathological risk factors for recurrence in patients with early stage cervical carcinoma treated 
with radical hysterectomy and pelvic lymphadenectomy.  
 
OBJECTIVES: 
1. To evaluate the 5 year survival rate of patients with stage IA-IIB who underwent 
Radical Hysterectomy with Pelvic lymphadenectomy. 
2. To evaluate the progression free survival of the patients who underwent this radical 
surgery. 
3. To assess the treatment related complications. 
4.  To determine the incidence of recurrence of disease after surgery and to investigate 
the distribution of risk factors among patients with recurrent tumours and 
5. To determine the impact of adjuvant therapy in particular patients. 
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REVIEW OF LITERATURE  
Globally cervical cancer constitutes 13% of all cancers occurring in women. It is the 
second most common cancer in women worldwide but in India and other developing countries it 
is the most common cancer in women(2). Cervical cancer is the third largest cause of carcinoma 
mortality in India after cancer of oropharynx and esophagus. The disease is preventable by 
screening, early diagnosis and treatment. Cervical intraepithelial neoplasia (CIN) is the 
preinvasive stage of cervical carcinoma. Human papilloma virus is considered as the causative 
agent in most cases of cervical cancer. 
Epidemiology  
Cervical cancer accounts for 530000 new cases and 27500 deaths in the year 2008.(3). 
Eighty three percent of new cases and eighty five percent of deaths from cervical cancer occur in 
developing countries. Worldwide there is an 8 fold variation in the incidence of cervical cancer. 
The highest incidence rates are found in South-Central Asia, South-East Asia and Sub-Saharan 
Africa. In developed countries, the incidence is low with age-standardized rates less than 14 per 
1, 00,000 women. The low risk in developed countries is due to effective screening 
programmes.(4)  
Age adjusted cervical cancer mortality rates exceed 15 per 1, 00,000 women in 
developing countries and this high rates are due to advanced clinical stage at the time of 
presentation. A significant number of patients do not receive complete treatment in many 
developing countries due to deficiencies in accessibility, availability and affordability of 
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treatment. But mortality rates never exceed 5 per 1, 00,000 women in developed countries due to 
successful screening programmes. 
  High survival is observed in developed countries than developing countries. According to 
SEER registries, five year survival is higher in Europe and Singapore whereas in India, Thailand 
and China the rates are fair (5). In India the current estimates indicate 132000 new cases and 
74000 deaths annually with an incidence of 23.5/1,00,000.(1). Thus India shares about one fourth 
of the global cervical cancer burden. The exact incidence is difficult to obtain due to under 
reporting in rural areas. Cervical cancer mostly affects middle aged women between 40 – 55 
years from lower socioeconomic status because of financial constraints to carry out regular 
health check-ups.   
The age distribution of cervical cancer is bimodal with 2 peaks, one between 35 – 40 
years and second between 55 – 65 years. But recent statistics in India showed that age specific 
incidence increases from 35 years to peak between 55 – 65 years. The mean age at diagnosis is 
around midforties in India and at 47 years in the west. 
Risk factors:  
1. Age (35 - 45 years) 
2. Low socioeconomic status 
3. Ethnicity 
4. Early sexual activity ( younger than 16 years ) 
5. Multiple sexual partners 
6. Partner with multiple sex partners 
7. Sexually transmitted infections 
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a. Gonorrhea 
b. Chlamydial infections 
8. Smoking 
9. Combined OCP   
10. Immunosuppression  
a. Genetic 
b. HIV infection 
c. Autoimmune diseases 
d. Hodgkin’s disease, leukemia 
e. Immunosuppressive drugs 
Pathogenesis  
HPV infection 
The causative agent in cervical dysplasia and cervical carcinoma is HPV infection. HPV 
is a circular, double stranded DNA virus which infects epithelial cells. More than 100 genotypes 
have been identified so far, out of which 30 – 40 types infect the lower genital tract. The 
genotypes which cause benign lesions are called low risk HPVs and those that cause malignant 
change are called high risk HPVs. (6) 
Table 1:     HPV genotypes 
HPV group Genotypes  
Low risk HPV 6, 11, 40, 42,44, 54, 61,72, 81 
High risk HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82 
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Figure 1:                HPV genome and mechanism of carcinogenesis 
 
 
 
The HPV genome is surrounded by icosahedral capsid composed by two structural 
proteins, L1 and L2. L1 is the major capsid protein where as L2 is the minor capsid protein. The 
viral genome is divided in to three parts – about two thirds codes for six early structural proteins 
E1 to E7, about one third codes for the late structural proteins L1 and L2. The papilloma virus 
infects only the epithelium. In the cervix the virus enters through micro trauma to the immature 
portion of the transformation zone adjacent to the SCJ, where the metaplastic squamous 
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epithelium consists of immature basal and parabasal type cells. When the cell is infected, the 
virus remains in latent form and this is called as latent infection. Latent infections are detected by 
HPV DNA hybridization. After an initial HPV infection, the infection clears spontaneously due 
to host immunologic defense mechanism. However in some individuals the virus continues to 
replicate and large numbers of complete virions are produced. This is called as productive viral 
infection. During this period viral replication occurs in intermediate & superficial cells. These 
latent and productive viral infections may be clinically unrecognizable or they may cause genital 
warts but they do not result in malignant transformation of the cells. 
Virus – host interaction is important for the transformation of normal epithelial cells to 
neoplastic cells. The initial event is the interaction of viral DNA into host chromosomes. The 
episomal virus that is present in latently or productively infected cells is in a circular form and 
the host DNA is in linear form, a change in the  physical form of virus should take place before 
the viral DNA is integrated into the host chromosome. The mechanism by which it is happening 
is not yet understood, however the circular strand of DNA is opened and the linear DNA is 
spliced into the host DNA and then it undergoes replication inside the host chromosome. The 
mechanism by which HPV affects cellular growth and differentiation is by interaction of viral E6 
protein with p53 and E7 with Rb. Inhibition of p53 prevents cell cycle arrest and cellular 
apoptosis whereas inhibition of Rb disrupts transcription factor E2F which results in unregulated 
cellular proliferation.(7). Both steps results in malignant transformation of cervical epithelial 
cells. 
The majority of HPV infections are transient and clear within a few months to years. 
Approximately 70% of infections resolve within a year, 90% resolve within 2 years.(8). Only 
25% of women infected with high risk HPV will develop cervical intraepithelial neoplasia and 
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1% will develop invasive cervical carcinoma. The time interval between infection and 
development of invasive cancer is around 10 – 20 years. The humoral immunity does not play a 
major role to prevent HPV infection because the virus is not cytolytic and it does not have blood 
borne stage. HPV infections are cleared by cell mediated immunity in which T helper cells and 
dendritic cells play major role. 
HPV vaccination 
Primary prevention of cervical cancer is by HPV vaccination. Two HPV vaccines 
quadrivalent Gardasil (HPV 16, 18 and 6, 11) and bivalent Cervarix (HPV 6 and 11) are 
approved by U.S FDA and protect against cervical cancer. Both vaccines are nearly 100% 
effective in protection against HPV infection which was proved in clinical trials.(9). The 
duration of efficacy is about 5 years. Long term protection is unknown and booster doses are 
necessary to maintain immunity. The vaccine should be administered at the age of 9 – 13 years, 
can be given up to 25 years. However it should be given before the onset of sexual activity since 
neither vaccine has therapeutic activity for preexisting infections. Three doses should be given as 
three intramuscular injections over six month period (Gardasil at 0, 2 and 6 months and Cervarix 
at 0, 1 and 6 months).(10). There are some barriers for the implementation of HPV vaccines in 
developing countries like India. One of the major barriers is cost of the vaccine. The three doses 
of Merck quadrivalent vaccine will cost $360 USD in U.S. So price reduction is required their 
use in developing countries with involvement of government or other non-governmental 
organizations (NGO) to bear the cost of the vaccines. 
The first generation vaccines (Gardasil & Cervarix) may not be the  ideal vaccine in low 
resource settings so research is going on to develop other vaccines which have broader range of 
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activity, long shelf life, provide long lasting immunity with single dose and no booster dose, 
cheaper and easy to use, without requirement of cold chain, both prophylactic and therapeutic 
and has non invasive routes of administration (oral or nasal spray).(11). The second generation 
vaccine in the clinical trial is a nonavalent (9-valent) vaccine. In addition to the HPV types 6, 11, 
16 and 18, the 9-valent vaccine target against other types i.e. 31, 33, 45, 52 and 58. It has 
additional 15-30% potential to reduce the incidence of cervical cancer.(12).  These HPV 
vaccines protect only against certain types of HPV, hence vaccinated women need to continue 
screening according to guidelines.(13). 
Pathology 
Histological types of cervical cancer 
1. Squamous cell carcinoma  
- Large cell keratinizing 
- Large cell non-keratinizing 
- Small cell carcinoma 
2.  Adenocarcinoma  
- Endocervical 
- Endometriod 
- Papillary villoglandular 
- Serous 
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- Clear cell 
- Mesonephric 
3. Mixed cervical carcinoma 
- Adenosquamous 
- Glassy cell 
- Adenoid cystic 
- Adenoid basal epithelioma 
4. Neuroendocrine tumours 
- Large cell  
- Small cell 
- Classical carcinoid 
- Atypical carcinoid 
5. Others 
- Sarcomas 
- Lymphomas 
Squamous cell carcinoma 
The predominant type of cervical carcinoma is squamous cell carcinoma which 
comprises 80 – 85 % of cervical cancers.(14). Squamous cell carcinoma arises from the 
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ectocervical squamous epithelium. Large cell keratinizing tumors consist of tumour cells which 
forms irregular infiltrative nests with keratin pearls in the center. Large cell non-keratinizing 
carcinoma reveals individual cell keratinization but do not form keratin pearls. Small cell 
carcinoma is classified into poorly differentiated squamous cell carcinoma and small cell 
anaplastic carcinoma. Large cell tumors with or without keratinization may be well differentiated 
or moderately differentiated. These tumours have good prognosis.  
Small cell tumors are mostly poorly differentiated and they have poor prognosis.(15). 
Small cell anaplastic carcinoma has more aggressive course and infiltrates parametrial tissue and 
pelvic lymph nodes earlier and has poor prognosis. Other variants of squamous carcinoma are 
verrucous carcinoma and papillary carcinoma. Verrucous carcinoma resembles giant condyloma 
acuminate and it is locally invasive and rarely metastasizes. 
Adenocarcinoma   
Adenocarcinoma occur more frequently in young women and the number of cases of 
invasive squamous cell carcinoma decreases in recent years.(16). The reason for increase in 
Adenocarcinoma is related to decreasing incidence of squamous cell carcinoma secondary to 
screening programs, greater exposure to HPV and greater exposure to oral contraceptives. 
Adenocarcinoma in situ is the precursor of invasive Adenocarcinoma. Adenocarcinoma  has 
worse prognosis when compared to squamous cell carcinoma.(17). About 80% of 
adenocarcinoma is endocervical type with mucin production. The remaining types are 
Endometriod type, intestinal cell type, clear cell type or mixture of more than one cell type. One 
of the variant of adenocarcinoma is minimal deviation Adenocarcinoma (adenoma malignum) 
which is a well differentiated form and unusually the histology simulates that of normal 
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endocervical glands. Because of this, the tumour may not be recognized as malignant thereby 
causing delay in diagnosis. Earlier studies showed poor outcome but recent studies have found a 
favorable prognosis if it is detected earlier.(18). Another variant is villoglandular papillary 
adenocarcinoma, mostly affects young women who are using oral contraceptive pills. This tumor 
is well differentiated, has smooth well defined borders and is superficially invasive and rarely 
metastasizes.  
Adenosquamous carcinoma 
Carcinomas with mixture of both malignant glandular and squamous components are 
known as adenosquamous carcinoma. Adenosquamous carcinoma has poorer prognosis than that 
of  adenocarcinoma or squamous cell carcinoma.(19). Glassy cell carcinoma is one of the 
variants of adenosquamous carcinoma which is poorly differentiated carcinoma and resistant to 
radiotherapy. Other variants are adenoid basal carcinoma and adenoid cystic carcinoma. Adenoid 
cystic carcinoma tends to invade into adjacent tissues and may metastasize to lungs. 
Neuroendocrine carcinoma 
 Neuroendocrine tumours of the cervix are rare tumours and have aggressive malignant 
behavior and they metastasize very early. It is usually disseminated to liver, brain and bone at the 
time of diagnosis. Treatment consists of surgery, radiotherapy & chemotherapy. These tumours 
have poor prognosis. Small cell (neuroendocrine type) carcinoma of cervix is similar to small 
cell carcinoma of bronchus and is aggressive in nature. Combination chemotherapy with 
radiotherapy improves the survival rates in small cell carcinoma.(20). 
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Pattern of spread 
1. Direct invasion -   cervical stroma 
-Uterus 
-Vagina 
-Parametrium & pelvic side walls 
2. Lymphatic spread -  primary nodes 
-Para cervical 
-Parametrial 
-Internal iliac 
-External iliac 
-Obturator 
-Sacral nodes 
Secondary nodes 
-Common iliac nodes 
-Para aortic nodes 
-Inguinal nodes 
-Left supraclavicular nodes (scalene) 
3. Hematogenous spread -  liver, lungs & bone 
4. Intraperitoneal implantation 
Direct extension to parametrium can extend to pelvic side walls and cause ureteric 
obstruction which results in hydroureteronephrosis and renal failure. Uterine corpus and vagina 
are involved by upward and downward spread of tumour. Lymphatic spread first occurs to 
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paracervical and parametrial nodes and then spread in to secondary nodes. The left 
supraclavicular lymph node is involved in very advanced stage of disease. 
Table 2:    Incidence of pelvic and para aortic lymph node metastasis by stage 
Stage Positive pelvic nodes (%) Positive para-aortic nodes (%) 
IA1 ( ≤ 3mm ) 0.5 0 
IA2 ( > 3-5 mm ) 4.8 <1 
IB 15.9 2.2 
IIA 24.5 11 
IIB 31.4 19 
III 44.8 30 
IVA 55 40 
 
 
Lymphovascular space invasion (LVSI) 
 This is one of the prognostic factors. When LVSI is present, even when the disease is 
early stage we should consider radical surgery and adjuvant therapy.(21). 
Staging  
 Cervical cancer is a clinically staged disease. Cervical cancer is staged by FIGO staging 
system.  
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Table 3:      FIGO staging of carcinoma cervix (2008) 
Stage I The carcinoma is strictly confined to the cervix 
       IA Invasive carcinoma which can be diagnosed only by microscopy with 
deepest invasion ≤ 5mm and largest extension ≤ 7 mm. 
                  IA1 Stromal invasion of ≤ 3mm in depth and extension ≤ 7mm 
                 IA2 Stromal invasion of  >3mm and not >5mm and extension not  > 7mm 
       IB Clinically visible lesions limited to the cervix or pre clinical cancers  
greater than stage IA 
                  IB1 Clinically visible lesion ≤ 4 cm size 
                   IB2 Clinically visible lesion > 4cm in size 
Stage II Cervical carcinoma invades beyond the uterus but not up to the pelvic 
wall or lower one third of vagina 
             IIA Without parametrial invasion 
                 IIA1 Clinically visible lesion ≤ 4 cm size 
                IIA2 Clinically visible lesion > 4cm in size 
         IIB With obvious parametrial invasion 
Stage III The tumour extends up to the pelvic wall and / or involves lower one 
third of vagina and / or causes hydronephrosis or non-functioning 
kidney 
         IIIA Tumour involves the lower one third of vagina with no extension to 
the pelvic wall 
        IIIB  Extension to the pelvic wall and / or hydronephrosis or non-
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functioning kidney  
Stage  IV  Carcinoma has extended beyond the true pelvis or involved the 
mucosa of the bladder or rectum. A bullous edema does not belong to 
stage IV  
          IVA Carcinoma spread to the adjacent organs 
         IVB Carcinoma spread to distal organs. 
 
Cervical carcinoma staging is clinical because it is predominantly a disease of low 
resource setting where imaging and surgical staging may not be feasible or cost effective.  
Whenever there is doubt about the stage of the disease, always the earlier stage should be 
selected. Once the clinical stage is assigned and treatment is initiated the stage should not be 
changed by the findings of extended clinical staging or surgical staging. The staging procedures 
allowed by FIGO are given in the table. 
Table 4: 
Radiological studies Intravenous pyelogram 
 Barium enema 
 Chest X ray 
 Skeletal X ray 
Procedures Biopsy 
 Conization, colposcopy 
 Endocervical currettage 
 Cystoscopy, proctoscopy 
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CT scan, ultrasonography, MRI, PET scan, lymphangiography and laparoscopy are 
optional studies and they are not allowed by FIGO to change the clinical stage. CT scan is useful 
to visualize the pelvic and para aortic lymphadenopathy, liver, urinary tract and skeletal 
metastasis. Parametrial infiltration is best assessed by MRI.(22). PET scan identifies microscopic 
metastasis in nodes and used to evaluate the paraaortic nodes for extended field radiation.  
Surgical staging 
The purpose of the surgical staging is to identify the para aortic lymph node metastasis in 
clinically advanced disease. This can be done Laparotomy (transperitoneal or extra peritoneal) or 
laparoscopically. When the nodes are positive, they can be debulked and extended field radiation 
can be given. This procedure is associated with complications such as injury to blood vessels and 
ureter. The benefit of surgical staging is questionable especially when MRI and PET scan are 
available to find out nodal status.(23). Hence surgical staging is routinely not recommended.(24). 
Clinical presentation  
Classical symptom of cervical carcinoma is abnormal vaginal bleeding which may be in 
the form of menorrhagia, metrorrhagia, postcoital bleeding or postmenopausal bleeding. When 
the disease is in advanced stage, patients will have profuse malodorous vaginal discharge and 
sometimes the discharge may be blood stained. Advanced disease when infiltrates the nerves can 
give rise to pelvic pain and radiating pain along sciatic nerve distribution. Obstruction to veins 
and lymphatics cause pedal edema. When tumour infiltrates the bladder or rectum give rise to 
hematuria, urinary or fecal incontinence due to formation of fistula.  
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 Invasive cervical lesions can be ulcerative, exophytic, infiltrative or occult. The size of 
the lesion which is seen on the cervix may not correlate with depth or extent of invasion. The 
exophytic lesions are friable, fungating, fixed or indurated and it bleeds on touch during 
speculum and bimanual examination. Parametrial infiltration can be felt on rectal examination. 
Usually uterus is normal in size or when there is pyometra; uterus is uniformly enlarged and 
tender. This is seen in postmenopausal women or when the growth is endophytic and obstructing 
the cervical canal.  
Diagnosis  
Cervical cancer is always a clinical diagnosis which is confirmed by biopsy. Pap smear is 
not necessary when there is an obvious growth. Punch biopsy should be taken from the edge of 
the lesion by punch biopsy forceps. If the lesion is not visible and the cytology is abnormal, 
colposcopy and directed biopsy is required or cone biopsy.(25). Barrel shaped cervix with 
endophytic lesion needs endocervical curettage. 
Pretreatment evaluation 
 Women with advanced stage of disease require cystoscopy, proctoscopy and IVP. When 
chemoradiation is planned complete blood count, liver and renal function test should be 
performed. CT, MRI and PET scan are not advised by FIGO staging, however they can be done 
in particular situation to assess para aortic metastasis. Women in early stage of disease, to rule 
out parametrial infiltration MRI is useful. 
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Treatment  
 The therapeutic modalities are surgery, radiotherapy, chemotherapy or chemoradiation. 
Surgery is limited to early stages – stage I to IIA disease but radiotherapy can be used in all 
stages of disease.(26). The 5 year survival rate for stage I cancer is approximately 85 % with 
either radical hysterectomy or radiotherapy. 
 In younger women whom conservation of ovaries is important, surgery is better than 
radiotherapy.  The advantages of radical surgery over radiation therapy are accurate evaluation of 
extent of the disease, preservation of ovarian function and sexual function , fewer late 
recurrences and complications and psychological satisfaction that the tumor has been 
removed.(27). Chronic bladder or bowel complications are commonly occurring in radiotherapy 
and these complications are difficult to treat because they result from fibrosis and decreased 
vascularity. Sexual dysfunction occurs after radiation due to fibrosis, vaginal shortening and 
atrophy of epithelium.(28). Vagina becomes shorter after surgical therapy but it remains soft, 
moist, pliable and gradual lengthening can be brought by sexual activity. The epithelium will 
also respond to exogenous estrogen unlike atrophic epithelium after radiation. 
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Treatment of invasive cancer of the cervix 
Stage IA1  ≤ 3mm invasion, no LVSI  Conization or type 1 hysterectomy 
≤ 3mm invasion with LVSI Radical trachelectomy or type II 
radical hysterectomy with pelvic 
lymphadenectomy 
Stage IA2  > 3-5mm invasion    ” 
Stage IB1  < 2cm     Radical trachelectomy or type III   
      radical hysterectomy with pelvic  
      lymphadenectomy 
>2 cm     Type III radical hysterectomy with  
      pelvic lymphadenectomy 
Stage IB2       Type III radical hysterectomy with  
       pelvic and para-aortic lymph  
       adenectomy or primary chemo 
       radiation 
Stage IIA1, IIA2       "  
Stage IIB, IIIA, IIIB      Primary chemoradiation 
Stage IVA       Primary chemoradiation or primary 
        exenteration 
Stage IVB       Primary chemotherapy ± radiation 
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 Micro Invasive carcinoma 
 According to FIGO, micro invasive carcinoma is defined as a tumour invaded to a depth 
of < 3mm with the horizontal spread < 7mm. According to SGO, a lesion with depth of invasion 
is  ≤  3mm with no evidence of LVSI.(29). 
Stage IA1 Squamous cell carcinoma 
 Invasive carcinoma which can be diagnosed only by microscopy is stage IA1 or 
preclinical carcinoma. Women with IA1 are mostly asymptomatic and are diagnosed during 
evaluation of abnormal cytology. Definitive diagnosis of microinvasion can be made only in 
conization specimens.  
 Cone biopsy has both diagnostic and therapeutic role in cervical carcinoma. It can be 
done in stage IA1 patients who want to preserve their fertility.(30,31). However there should be 
no evidence of LVSI, negative margins and ECC should be negative for dysplasia or cancer. 
Stage IA1 cancer has less than 1% risk of lymphnode metastasis, so lymphadenectomy is not 
necessary. If the cone margins or post conization ECC is positive for dysplasia or micro invasive 
carcinoma further treatment should be done because these findings are strong predictors for 
residual disease.(32). The risk of residual disease is 4% if both ECC and margins are negative , 
22% if the ECC alone is positive and 33% if both are positive.(33). 
Treatment of stage IA1  
Simple (Extrafascial) Hysterectomy 
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 Simple hysterectomy or type I hysterectomy is an appropriate treatment option for 
patients with stage IA1 tumors without LVSI and not desirous of fertility. Lymphadenectomy is 
not required in such cases. If LVSI is present, type II hysterectomy or modified radical 
hysterectomy with pelvic lymphadenectomy is an effective therapy. 
Radical trachelectomy  
  Radical trachelectomy is the treatment option for women with stage IA2 and IB1 
who wants to preserve their fertility.(34). The ideal candidates are tumors with negative lymph 
nodes and the size is less than 2cm. This can be done abdominally, vaginally, laparoscopically or 
robotically and pelvic lymphadenctomy and cervical cerclage should be done along with 
trachelectomy. The lymphadenectomy should be done initially by laparotomy, laparoscopy or 
robotic surgery and depending on these results the further procedure can be continued or 
abandoned. A retrospective study compared the outcome & recurrence in patients treated with 
either laparoscopic radical hysterectomy or laparoscopic radical trachelectomy showed similar 
outcomes and recurrence.(35). Studies showed that 5 year cumulative pregnancy rate is 53% 
with high miscarriage rate.(36). 
Stage IA2 
 The incidence of pelvic lymph node metastasis is around 4.8% and local recurrence rate 
is 3 - 3.4%. The treatment option is modified radical hysterectomy (type II hysterectomy) and 
pelvic lymphadenectomy. Women who want to preserve fertility can be treated with radical 
trachelectomy and laparoscopic pelvic lymphadenectomy. 
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Stage IB1 and IIA 
 Treatment options for stage IB1 and IIA are similar and can be treated by radical 
hysterectomy (type III) with pelvic lymphadenectomy or radiotherapy since both modalities of 
treatment have same cure rate. In young women who desire fertility, size is less than 2cm and 
stage IB1 radical trachelectomy and pelvic lymphadenectomy can be performed. 
Stage IB2 
 Tumor size > 4cm have higher incidence of lymph node metastasis and local, regional 
and distant metastasis. The treatment of this stage is controversial and the treatment options are 
as follows: 
a) Primary radiation followed by simple hysterectomy 
b) Chemoradiation followed by simple hysterectomy 
c) Neoadjuvant chemotherapy followed by radical hysterectomy.(37). 
d) Primary radical hysterectomy and postoperative radiation. 
Radical hysterectomy with pelvic lymphadenectomy and postoperative radiation is the 
treatment of choice in many centre.(38). There are several advantages to primary surgical 
approach. It allows accurate staging of disease, removal of primary cancer, resection of bulky 
positive lymph nodes and in premenopausal women there is preservation of ovarian function.  
Stage IIB to IVA 
 These stages are advanced stage of disease and it spreads to the parametrium and adjacent 
organs. The choice of treatment is chemoradiation. Recurrence rate is high and survival rate is 
low in this group of patients. 
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Stage IVB 
 This stage has very poor prognosis due to distant metastasis. Palliative radiotherapy and/ 
or palliative chemotherapy are the treatment of choice in this group of women. 
 Types of Hysterectomy 
Extrafascial Hysterectomy (type I) 
This is simple hysterectomy and this is the treatment option for stage IA1 cervical 
carcinoma.  
Modified Radical Hysterectomy (type II) 
This is described by Ernst Wertheim. The uterine artery is ligated where it crosses the 
ureter and proximal uterosacral ligaments, the medial half of the cardinal ligaments and the cuff 
of the vagina are resected. It includes removal of  pelvic lymph nodes also.(39). 
Radical Hysterectomy (type III) 
This is described by Meigs in 1944 includes removal of uterus with cervix along with 
excision of most of the uterosacral and cardinal ligaments and the upper one third of vagina and 
pelvic lymphadenectomy. The uterine artery is ligated near to  its origin  from the internal iliac 
artery or superior vesical artery.(40),42). 
The modified radical hysterectomy differs from radical hysterectomy in the following 
ways: 
1. The cardinal ligament is divided in midportion near the ureteral dissection. 
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2. Uterine artery is transected at the level of ureter thus preserve the ureteral branch. 
3. The anterior vesicouterine ligament is divided but the posterior ligament is conserved. 
4. Small margin of vagina is removed. 
Extended Radical Hysterectomy (type IV) 
 In this operation superior vesical artery, periureteral tissue and three fourth of vagina are 
removed. The chances of ureteric fistula are high in this procedure. 
Partial Exenteration (type V) 
 In this operation portion of the distal ureter and bladder are removed. This is rarely 
performed because radiotherapy should be used when extensive disease is present. 
 
Surgical Technique of Radical Hysterectomy  
 Patient is positioned in semi lithotomy position with stirrups. Pneumatic calf compressors 
are used during surgery. After positioning the patient, a careful abdominal and rectovaginal 
pelvic examination should be done. After cleaning and draping, catheterization is done and the 
operation is begun. The abdomen is opened either lower midline incision or through a low 
transverse Maylard or Cherney incision. After entering the peritoneal cavity all abdominal 
organs are systematically palpated for evidence of metastatic tumour. The undersurface of 
diaphragm and superior and inferior surface of liver are carefully palpated. The serosal surface of 
the bowel along with omentum, mesentry of small and large bowel should be examined for any 
evidence of metastatic tumour. The retroperitoneal space, kidneys, aorta and inferior vena cava is 
palpated because these are sites of extra pelvic spread of tumour. 15% of paraaortic node 
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metastasis is occult; therefore any suspicious node should be removed and sent for frozen section 
analysis. If histopathological evidence of tumour in paraaortic node, the surgery should be 
abandoned and these patients should receive chemoradiation.(42). 
 After exploration of the abdomen, the bowel is placed in the upper abdomen with moist 
packs. Now the extent of pelvic tumour and pelvic lymph nodes along with pelvic vessels are 
examined and any suspicious nodes are found, they are removed and sent for frozen section. The 
base of broad ligament, base of the bladder, lateral pelvic wall should be thoroughly examined. 
When there is evidence of extra cervical spread of disease, the procedure may be 
abandoned.(43). 
A decision should be made about removal or conservation of ovaries before the pelvic 
planes and spaces are developed. The procedure starts with clamping, cutting and ligating the 
round ligaments. If ovaries are conserved, the utero-ovarian ligaments are clamped, cut and 
doubly ligated. 
Development of Para-vesical Space 
 The para-vesical space is bounded by: 
1. Anteriorly - pubic symphysis 
2. Posteriorly – cardinal ligament 
3. Medially – obliterated umbilical artery along with bladder 
4. Laterally – obturator internus muscle 
The anterior leaf of broad ligament forms the roof of this space and it blends with the 
bladder peritoneum medially and the parietal peritoneum laterally. The floor is formed by levator 
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ani muscle. This fossa contains loose connective tissue and fat. After clamping and ligating the 
round ligament midway along its course, the anterior leaf of the broad ligament is opened 
inferiorly and extend deep into the pelvis before reflecting the bladder peritoneum from the 
lower uterine segment. Then the para-vesical space is entered with gentle digital pressure and the 
dissection is carried up to levator ani muscle. This space is avascular; occasionally there will be 
an aberrant obturator vessel from the inferior epigastric artery which courses along the posterior 
aspect of the pubic bone to the obturator space. 
Development of Para rectal Space 
 The para-rectal space is bounded by: 
1. Anteriorly – cardinal ligament 
2. Posteriorly – sacrum 
3. Medially – rectum and uterosacral ligament 
4. Laterally – hypogastric artery 
The floor is formed by levator ani muscle. This space is entered by extending the incision 
in the anterior leaf of broad ligament cephalad along the lateral margin of infundibulo pelvic 
ligament. By retracting the uterus medially the uterosacral ligament is stretched and the para-
rectal space is widened. Dissection of this space is precarious than para-vesical space and 
unskilled dissection leads to troublesome bleeding from small veins deep in the fossa. The 
hypogastric artery and vein are situated in the deeper aspect of this fossa along with levator ani 
muscle. When the examining finger reaches the pelvic floor, the fossa narrows and care should 
be taken to avoid damage to the lateral sacral and hemorrhoidal vessels.  
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When the para-vesical and para-rectal spaces are developed, the pelvic floor and cardinal 
ligament can be easily palpated. When the tumour is not extended in these areas, the surgery is 
proceeded further for lymph node dissection. 
Pelvic Lymphadenectomy 
  Dissection of the lymphatic tissue along the course of the iliac vessels should be started 
from the region of the bifurcation of the common iliac artery and extend superiorly up to the 
bifurcation of the aorta and inferiorly up to the deep circumflex iliac vein and inguinal ligament. 
The posterior leaf of the broad ligament is opened and extended up to the pelvic brim. Here 
ureter is identified when it enters the pelvis at the bifurcation of the common iliac artery. While 
dissecting the presacral area in the angle of the bifurcation of the aorta, avoid injury to middle 
sacral vessels and proximal part of the left external iliac vein.  Small vascular clips can be 
applied over the middle sacral vessels to prevent bleeding, in case if traumatized the venous 
bleeding is controlled by positive pressure against sacrum and with vascular clips. The lymphatic 
tissue along the common iliac vessels is removed by sharp dissection, while care is taken to 
avoid injury to the ureter. The ureter is retracted medially along with the parietal peritoneum to 
preserve the blood supply. 
 It is essential to remove the loose areolar tissue and fascial sheath from the iliac vessels 
but care should be taken to avoid injury to the wall of the vessels (intima). The pelvic vessels 
mainly the common iliac and external iliac vessels are rotated medially and laterally with a vein 
retractor in order to obtain the posterior lymphatic chain along the psoas muscle. The genito 
femoral nerve which lies lateral to the external iliac vessels should be preserved. When the nerve 
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gets damaged, it produces postoperative discomfort in the medial aspect of the thigh and the 
groin. 
 The external iliac vessels are dissected down to level where the deep circumflex iliac 
vein crosses the external iliac artery. Care should be taken to avoid injury to the inferior 
epigastric artery and vein at this point, which arise from the anterior and medial side of iliac 
vessels and course along the anterior peritoneum to the lower abdominal wall. 
The obturator space is entered by blunt dissection by reflecting the external iliac vessels 
medially from the psoas muscle and the lateral pelvic wall. The external iliac vessels are 
retracted laterally with a vein retractor and the obturator space is clearly exposed. The lymphatic 
tissue and the areolar tissue are dissected from the obturator space without injuring the obturator 
vessels and nerve. The dissection is continued further by removing all the nodes below the iliac 
vessels bifurcation. A lymph node present in the angle formed by hypogastric arteries and the 
external iliac arteries should be carefully dissected avoiding injury to the hypogastric vein. 
The common iliac vessels are retracted medially to expose the lateral common iliac 
nodes. Here the obturator nerve will be seen entering the obturator fossa through the psoas 
muscle.  The lumbosacral plexus nerve roots also are explored. The obturator artery is identified 
when it passes along the lateral pelvic wall adjacent to the obturator nerve.  The artery, vein and 
nerve run toward the obturator foramen through which they leave the pelvis. Care should be 
taken to avoid injury to these structures. Same procedure should be done in opposite side also to 
complete the pelvic lymphadenectomy. 
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Dissection of Hypogastric Artery, Uterine artery, Bladder and Ureter 
  After identifying the visceral branches of hypogastric artery, the artery is dissected. The 
anterior divisions of the hypogastric artery continue downwards along the para-vesical fossa as 
obliterated lateral umbilical ligament beneath the anterior abdominal wall. The uterine artery is 
doubly ligated at its origin from the hypogastric artery preserving the superior vesical artery. 
Care should be taken to avoid injury to the hypogastric vein. 
  The bladder is then reflected from the lower uterine segment by dissecting the bladder 
peritoneum from the uterus. The base of the bladder is released from the fascial adhesions by 
sharp dissection. The ureter tunnels between the anterior fascial bundles of the base of the broad 
ligament which is called as vesicouterine ligament. This tunnel is opened carefully by sharp 
dissection. The uterine artery and the vein run along the roof of this ligament. The anterior 
vesicouterine ligament is ligated and divided to expose the posterior ligament. Now the ureter is 
freed from its attachment to the posterior leaf of the vesicouterine ligament. The posterior 
ligament is ligated in radical hysterectomy but it will be conserved in modified radical 
hysterectomy. While doing ureteric dissection, care must be taken to prevent injury to muscular 
wall and adventitia of the ureter which contains nutrient vessels. If these vessels are injured it 
results in ischemic injury which leads to fistula formation in the postoperative period. 
Dissection of the cardinal ligament 
 The cardinal ligament is excised from the lateral pelvic wall and ligated with delayed 
absorbable suture. Multiple clamps are applied until the dissection is completed up to the pelvic 
floor and along the paravaginal tissues. If bleeding occurs during this time, hemostasis is 
obtained by firm packing of pelvis. 
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Dissection of uterosacral ligament 
   The uterosacral ligaments arise from a posterolateral part of cervix and run posteriorly to 
the anterolateral aspect of the rectum. They have wider attachment to the rectum than cervix due 
to broadening of the ligament when it approaches rectum. The ligaments get stretched when the 
uterus is drawn forwards. Then the peritoneum of the pouch of Douglas is incised and care 
should be taken to avoid injury to the ureter which is attached to the peritoneum just lateral to the 
uterosacral ligament. The recto vaginal space is opened by sharp dissection and it is deepened by 
sharp and blunt dissection. The uterosacral ligament is identified, clamped as far as possible 
posteriorly and close to the anterior rectal wall, cut and ligated. The dissection is continued along 
the posterior endopelvic fascia which frees the posterior aspect of the cervix from the pelvic 
floor. 
 The paravaginal fascia should be dissected in order to obtain the lymphatic channels 
communicate between the cervix and the upper vagina. The bladder is further dissected down 
from the upper portion of the vagina by sharp dissection avoiding trauma to the blood supply to 
the bladder. Now right angled Wertheim clamp is placed below the cervix to prevent spillage of 
tumour cells in to the pelvis. The specimen is then removed by dividing the vagina above clamps 
placed on the lateral vaginal angles. 
Closure 
The angle of the vagina is sutured separately to obtain hemostasis and then the vaginal 
cuff is closed with continuous locking 2-0 delayed absorbable suture. The remaining vagina is 
supported by urogenital diaphragm and levator ani muscles and by postoperative fibrosis during 
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the healing phase. Drainage of pelvic and para aortic lymph node beds is not done nowadays 
because it increases the complications.(44). 
The ovaries should be transposed out of pelvis in a patient who needs postoperative 
radiotherapy. A tunnel is created beneath the peritoneum in each lateral gutter. The adnexal 
structures are guided through the tunnel and the ovarian vessels in the infundibulopelvic 
ligament should not be twisted.  Permanent suture material is used for this ovarian suspension 
procedure.  
Laparoscopically assisted Radical Vaginal Hysterectomy (Schauta)  
The radical vaginal hysterectomy for cervical cancer was described by Schauta in Austria 
in 1901. Initially Schauta operation did not include pelvic lymphadenectomy so it became less 
popular. In 1959 Mithras combined Schauta operation with retroperitoneal approach for pelvic 
lymphadenectomy. In recent trend, the Schauta operation is preceded by laparoscopic pelvic 
lymphadenectomy.(45). 
Over the last two decade, studies have shown that LARVH is a safe procedure with low 
morbidity rate. Studies comparing abdominal radical hysterectomy with LARVH showed that 
LARVH has longer operative time but less blood loss and hospital stay. Yield of lymph nodes 
are similar in both groups. Intra-operative complications are more in LARVH group but 
postoperative complications are more in Laparotomy group. But there is no significant difference 
in overall survival and recurrence rate. (46). This procedure is ideal in women who have tumour 
< 2cm, negative LVSI with negative nodes.  
In one series, 200 women with stage IA1 to IIB cervical cancer patients treated with 
laparoscopic assisted radical vaginal hysterectomy. The authors found that 5 year survival rate is 
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comparable to Radical abdominal hysterectomy and a comparable rate of intra-operative 
complications.(47). This technique has less blood loss, shorter hospital stay and faster 
recovery.(48,49). 
Nerve sparing Radical Hysterectomy 
 This surgery is proposed by European surgeons to prevent bladder, bowel and sexual 
dysfunction. The superior hypogastric plexus is located in sacral promontory, from there two 
hypogastric nerves which contain sympathetic fibers arise and run beneath the ureter and these 
are responsible for urinary continence, bladder compliance and orgasm. These superior 
hypogastric nerves fuse with parasympathetic fibers from S 2, 3, 4 and form inferior hypogastric 
plexus. This plexus is situated in the dorsal vesicouterine ligament and the dorsal part of the 
parametrium. The parasympathetic fibers are responsible for detrusor contractility, rectal 
functions and sexual functions. 
 The steps of this surgery are a) the hypogastric nerve is identified and preserved at the 
level lateral to uterosacral ligament and beneath the ureter, b) inferior hypogastric plexus is 
avoided during parametrial dissection, c) the most distal part of the inferior hypogastric plexus is 
preserved during dissection of the posterior vesicouterine ligament. Studies have shown that 
nerve sparing radical surgery has less bladder, bowel morbidity.(50). The disease free survival 
rates are comparable to non nerve sparing surgery but there is no significant difference in local 
recurrence rate and postoperative complications. The blood loss is less and lesser duration of  
hospital stay with nerve sparing technique.(51).   
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Robotic Laparoscopic Radical Hysterectomy 
Robotic laparoscopic radical hysterectomy is a new technique; it will decrease the 
surgical morbidity especially in obese patients. Studies compared the surgical outcomes of this 
technique with open technique showed that robotic cases had shorter hospital stay, minimal 
blood loss with less operative complications. Operative time and lymph node yield are 
acceptable but they have larger incidence of postoperative bladder dysfunction(2.4%). (52,53).  
Sentinel lymph node evaluation 
 Sentinel lymph node dissection is used in the treatment of melanoma, breast cancer and is 
investigational in the management of cervical carcinoma. The sentinel node is the first node to 
receive drainage from the malignancy and it is the primary site of nodal metastasis. It reflects the 
nodal status of a particular patient and so if negative sentinel node; it indicates omission of 
lymphadenectomy in that patient. Sentinel lymph nodes are identified by perilesional injection of 
radiolabelled technicium-99 or blue dye followed by using gamma probes or visual identification 
of blue stained nodes. Sentinel lymph node biopsy is used in early stage disease with negative 
nodes but not in advanced stage of disease.(54). 
 Sentinel nodes are detected in 80% to 100% of cervical cancer patients with sensitivity of 
65- 80% and 90-95% of negative predictive value. It has high false negative rate due to limited 
abilities to detect micrometastasis. Bilateral ultrastaging of sentinel lymph node will decrease the 
false negative rate and increases the detection of micrometastasis.(55). 
Complications of Radical Hysterectomy 
 
 43 
 
Intra-operative complications 
 The main intra-operative complication is blood loss, the average blood loss varies 
between 800-1500ml. Intra-operative injury to bladder, ureter, rectum, pelvic vessels and 
obturator nerve are also common.(56). These injuries should be recognized and repaired 
immediately.(57). 
Postoperative complications 
 Early complications: 
  The early complications are as follows, 
1.  Urinary tract infections 
2. Venous thrombosis 
3. Pulmonary embolism 
4. Ureterovaginal fistula 
5. Vesicovaginal fistula 
6. Fever 
7.  Lymphocyst 
8. Ileus 
9. Burst abdomen 
Urinary tract infection is the most common complication. Voiding dysfunction needs 
prolonged catheterization. Febrile morbidity is due to pulmonary infection (10%), wound 
infection and pelvic cellulitis (7%). Pulmonary embolism, vesicovaginal or ureterovaginal 
fistulas occur in <1% of cases. (58). 
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Lymphocyst occurs in <5% cases. (59). Routine placement of retroperitoneal drains will 
not reduce this complication. Small lymphocyst will not cause any symptoms larger ones will 
cause lower abdominal pain on the same side with radiation to the back, hip and thigh and edema 
in the lower limb on the same side.  It will lead to ureteral obstruction, partial venous obstruction 
and thrombosis. Percutaneous catheters with lavage may heal the lymphocyst. If this is not 
successful, excision of a part of the lymphocyst wall with placement of omentum or large bowel 
should be performed. (60). Mann and coworkers reported injection of sclerosant like tetracycline 
will cause sclerosis of lymphocyst some have used povidone iodine sclerosis.  
Late complications:  
1. Prolonged bladder dysfunction 
2.  Lymphedema 
3. Sexual dysfunction. 
4. Ureteral stricture 
Bladder dysfunction 
 Bladder dysfunction(3%)  is the most distressing late complication, it needs continuous 
bladder drainage and in some cases, self catheterization.(61).  This neurogenic dysfunction is due 
to denervation of the bladder and urethra. The severity of dysfunction is directly proportionate to 
the extensive dissection of the surgery. Sympathetic and parasympathetic nerve fibers to and 
from the bladder and urethra is removed along with paracervical, paravaginal, cardinal ligament 
and pelvic lymph nodes.  Two abnormal patterns are found during cystometric evaluation of 
bladder dysfunction in postoperative period. Most common pattern is hypertonic bladder with 
decreased bladder capacity, increased urethral pressure and increased residual volume. The 
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hypotonic bladder occurs less frequently. Patients with hypertonic bladder have difficulty in 
initiating the micturition with normal filling sensation and feel the discomfort of full bladder. 
This is self limiting, within 3 weeks of surgery. Hypotonic or atonic bladder has worse 
prognosis, some require lifelong self catheterization.(62). 
 There are various techniques to manage the postoperative bladder like suprapubic 
catheter and indwelling catheter etc. Proper management of the bladder in first couple of weeks 
after surgery is important to prevent over distention of bladder.  The duration of postoperative 
bladder catheterization has decreased in recent years from 30 days to 6 days. Some clinicians 
advice suprapubic catheters for 2 – 3 weeks. After 2 weeks suprapubic catheter can be clamped 
and the patient should be assessed whether she feels fullness of bladder. If she has the urge to 
pass urine, the clamp should be removed and the bladder is emptied. If there is no retention of 
urine and the patient is voiding freely then the supra pubic catheter can be removed. 
Patients should be educated about frequent voiding and not allow the bladder to be over 
distended. Over distention results in flaccid bladder, stretching of detrusor muscles, high residual 
urine volumes and this will lead to urinary infections. UTI should be evaluated and treated with 
appropriate antibiotics.   
Sexual dysfunction 
 A study which was conducted in Sweden women analyzed sexual dysfunction in cervical 
cancer survivors showed 50% of sexual dysfunction occurs after radical hysterectomy alone.(63). 
The features are dyspareunia, reduced vaginal length and elasticity, insufficient lubrication and 
reduced genital swelling during sexual arousal. The addition of adjuvant radiotherapy further 
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increases the sexual dysfunction. In order to overcome this problem, nerve sparing hysterectomy 
was introduced with good results. 
Lymphedema 
 One of the late complications is lymphedema which is underestimated in literature. A 
retrospective study of 290 patients with cervical carcinoma who underwent radical hysterectomy 
with pelvic lymphadenectomy showed 9% of patients developed lymphocyst and only 2% had 
lymphedema. Most of them developed lymphedema within 6 months to 1 year of surgery. 
Postoperative adjuvant radiotherapy increases the risk of lymphedema.(64).  
Ureteral stricture 
 They are not common unless the patient had lymphocyst, postoperative adjuvant 
radiotherapy or recurrent cancer.(57). If the stricture is due to lymphocyst, treatment of 
lymphocyst alleviates the problem. If it occurs after radiotherapy, it should be managed with 
ureteral stenting. If the stricture occurs without lymphocyst or radiation then we should think in 
terms of recurrence of the disease. FNA should be done if there is target lesions and CT abdomen 
and pelvis is also mandatory. If these tests are negative, a stent should be placed to relieve the 
obstruction.  Close surveillance in necessary to rule out recurrence of the disease. 
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Table 5:     Various studies have shown different rates of postoperative complications of Radical 
Hysterectomy. 
Author  No of 
patients  
Wound 
infection 
(%) 
Ureteral 
injury 
(%) 
Bladder 
injury 
(%) 
Blood 
vessel 
injury 
(%) 
Urinary 
tract 
fistula 
(%) 
Bladder 
dysfunction 
(%) 
DVT 
and 
PE 
(%) 
Lympo 
cyst 
(%) 
Cai et al 
2009 
480 0.63 0.83 0.83 0.21 1.0 12.9 - 5.8 
Manchan 
et al 2009 
290 - - - - - 14.5 - 9.3 
Likic et al 
2008 
529 - 1.32 - - - - - - 
Pikart et al 
2007 
201 4.0 1.5 - - 0.5 7.5 1.5 1.0 
Wu et al 
2006 
219 - - - - 9.5 19.9 - 7.8 
Landoni et 
al 2001 
109 - 0.92 - - 0.92 14.7 2.8 11.9 
Zorlu et al 
1998 
115 10.4 0.87 2.6 8.7 - - - - 
 
 
 48 
 
Postoperative management  
Prognostic variables for Early stage cervical cancer 
 The survival outcome of patients with early stage cervical carcinoma after radical 
hysterectomy and pelvic lymphadenectomy depend on the presence or absence of intermediate 
and high risk factors. 
Intermediate risk factors for recurrence of disease are 
1. Large tumour size 
2. Stromal invasion to middle or deep one third 
3. Lympho-vascular invasion 
High risk factors for recurrence of disease are 
1. Positive lymph nodes 
2. Positive or close margins 
3.  Parametrial involvement 
 
Patients who underwent radical surgery with intermediate risk factors have 30% risk of 
recurrence and with high risk factors 40% risk of recurrence within 3 years. (65,66). 
Tumour size 
Size of the tumour is an independent predictor of survival. When the size is less than 2cm 
the survival rate is approximately 90%, size is more than 2cm the survival rate is 60% and if the 
size is more than 4cm the survival rate drops to 40%. (67).  
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Depth of invasion 
When the depth of invasion is less than 1cm, the 5 year survival rate is approximately 
90% and if it is more than 1cm the survival rate drops to 60-75%. (68). 
Parametrial invasion 
When the parametrium is involved the 5 year survival rate is 70% compared to 90% 
when it is not involved. When the lymph nodes and the parametrium are positive, survival rate 
drops to 40%. (69). 
Lympho-vascular space invasion (LVSI) 
LVSI is a predictor of lymph node metastasis and it is not an independent predictor of 
survival. Studies showed that if LVSI is present, 5 year survival rate is 50-70% and LVSI is 
absent, the rate increased to 90%. 
Lymph node involvement 
This is the important variable that predicts the 5 year survival rate. Patients with negative 
lymph nodes have approximately 85-90% survival  but it drops to 20-40%  if the nodes are 
positive depending on the number of nodes, size and location.(70). When more than three pelvic 
lymph nodes are involved the recurrence rate is 68% compared to 30-50% when less than three 
lymph nodes positive.(71). Bilateral positive pelvic nodes has less favorable prognosis than 
unilateral positive pelvic lymph nodes.  
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Positive vaginal margins 
When the vaginal margins are positive (< 5mm) survival rate is less and high chances of 
recurrence of disease. The 5 year survival rate is improved by postoperative adjuvant 
radiation.(72). 
Radiation therapy 
1. Primary radiation therapy 
2. Adjuvant radiotherapy 
3. Concurrent chemoradiation 
Primary radiation therapy 
Radiotherapy can be used in all stages of cervical cancer with the cure rates of 70% for 
stage I, 60% for stage II, 45% for stage III and 18% for stage IV, but most commonly used to 
treat advanced stage of disease. The survival rate of early stage cervical cancer treated with 
radical surgery or radiotherapy is more or less same approximately about 85%. (73). Primary 
radiation consists of external beam radiation to decrease the tumor volume and to treat the 
regional lymph nodes and brachytherapy to deliver a treatment boost to the central tumor. 
Brachytherapy is delivered by intracavitory applicators or interstitial implants. 
Mostly primary radiation is given along with chemotherapy as concurrent 
chemoradiation. The complications of radiotherapy depend upon the tumour volume. Smaller 
lesions (< 2cm) may be treated first with an intracavitory brachytherapy to treat the primary 
lesion followed by external RT to treat the pelvic lymph nodes. Larger lesions require external 
radiation to shrink the tumor followed by brachytherapy.   
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The external beam fields mainly targets the primary tumour, paracervical tissues, 
presacral nodes and iliac nodes with 2cm margins. If the common iliac nodes or paraaortic nodes 
are involved, extended field radiation should be given. There is no role of prophylactic para 
aortic radiation because it will increase the morbidity with no survival advantage. The external 
beam therapy is given as four field box technique. The borders are 
Superior – at L4-L5 junction which includes common iliac nodes 
Inferior – at the midpubis or 3-4cm below the distal disease in the in the cervix or vagina. 
Lateral – 1cm lateral to the bony pelvis. 
The external radiation is administered as fractions, 5 days in a week for 5 weeks (25 
fractions) with a total of 50 Gy. This is followed by intracavitory radiation which includes 
uterine tandem and two vaginal ovoids. The dose is delivered as low dose rate (LDR) over 36 – 
48 hours using Cesium 137 as radioactive source or high dose rate (HDR) once a week for two to 
three weeks using Iridium 192 as radioactive source. The total dose of radiation is calculated and 
delivered by Manchester method which uses two primary reference points.  
 Point A – 2cm above the external os and 2cm lateral to the cervical canal. 
 Point B – 3cm lateral to point A 
The total dose is 80-85 Gy at point A and 50-65 Gy at point B. Studies compared both 
LDR and HDR techniques in terms of overall survival, disease free survival, local control of 
disease, recurrence of disease and treatment related complications showed no significant 
differences between LDR and HDR intracavitory techniques.(74,75).  
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Intensity Modulated Radiation Therapy (IMRT) 
 Another form of external beam therapy is IMRT. This uses computer generated 
algorithms that distinguish between normal tissue and target tumour cells. The intensity is 
modulated to deliver the optimal dose to the tumour tissues while sparing the normal tissue. 
Studies have shown that this technique has minimal toxicity with good control of loco-regional 
tissue but there is no data on 5 year survival rate.(76). 
Adjuvant Radiation 
 Postoperative radiotherapy is advised for patients with high and intermediate risk factors 
for recurrence such as positive pelvic nodes, positive margins, positive parametrium and deep 
cervical invasion. The rationale for adjuvant radiation is that pelvic lymphadenectomy does not 
remove the entire nodal and lymphatic tissue and subsequent radiation can eradicate the 
microscopic disease. However this will increase the urinary tract and bowel complications. 
Retrospective studies showed adjuvant radiation for positive pelvic nodes significantly reduces 
recurrence rate but no significant difference in 5 year survival rate.(77). To improve the survival 
with adjuvant radiation, chemotherapy was added to the radiation. Studies also confirmed that 
postoperative chemoradiation improve the overall survival and disease free survival in patients 
with high risk factors than postoperative radiation alone.(78,79). 
Concurrent Chemoradiation 
  Chemoradiation is the treatment of choice for advance stage of cervical carcinoma and it 
can be given as postoperative adjuvant therapy for patients with high risk factors for recurrence. 
The purpose of chemotherapy is to sensitize cell to radiation therapy thereby improve the control 
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of disease. Cisplatin, 5 FU and hydroxyurea can be used as chemotherapeutic drugs. But 
cisplatin based chemoradiation is superior to other drugs and studies also confirmed that. 
Cisplatin is administered as 40mg/m2 weekly for 4 weeks along with external beam therapy. 
GOG protocol 120 evaluated overall survival and progression free survival in patients with 
advanced stage disease treated with chemoradiation with weekly cisplatin or cisplatin, 5 FU and 
hydroxyurea or hydroxyurea alone. This study showed improved overall survival and 
progression free survival in patients received cisplatin based chemoradiation.(80). 
 GOG, southwestern oncology group and radiation therapy oncology group (RTOG) 
evaluated postoperative chemoradiation in patients with stage IA2 to IIA with high risk factors 
after radical surgery. Chemoradiation included cisplatin, 5 FU and radiation therapy. This study 
showed statistically significant improvement in overall survival and disease free survival in 
patients receiving concurrent chemoradiation.(81). 
Complications of Radiation therapy 
 Uterine perforation can occur during insertion of uterine tandem. When perforation 
occurs, the tandem should be removed and the patient should be monitored for intra abdominal 
bleeding or signs for peritonitis. Fever can occur after insertion of uterine tandem and vaginal 
ovoids. In this case cephalosporin antibiotics should be given to prevent sepsis. If fever does not 
settle with antibiotics, the tandem and ovoids should be removed and the application should be 
delayed for 1-2 weeks. 
Acute complications   
 Acute complications are due to ionizing radiation on the epithelium of the bladder and 
bowel and it occurs when the dose is more than 20Gy. Symptoms are abdominal cramps, nausea, 
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diarrhea, frequent urination and occasional hematuria and bleeding per rectum. These bladder 
symptoms are treated with antispasmodics and bowel symptoms with low protein, low lactose, 
low gluten diet and antidiarrheal agents. When the symptoms are very severe, they require a 
week rest from radiotherapy. 
Chronic complications 
 Chronic complications are due to radiation induced vasculitis and fibrosis. These 
complications usually occur after several months to years after completion of radiotherapy. This 
results in bladder fistula(5%), bowel fistula(1%), enteritis and proctosigmoiditis.(82). 
Proctosigmoiditis  
 This results in bleeding per rectum, diarrhea and obstruction which is treated with a low 
residue diet and antidiarrheal medications. Very severe cases require recto sigmoid resection and 
colostomy. 
Rectovaginal fistula 
 Rectal stricture and rectovaginal fistula occur in less than 2% patients. Resection and 
anastomosis is warranted but those who had anastomotic leak or breakdown from previous repair 
requires diversion colostomy. 
Small bowel complications 
 Small bowel complications more commonly occurs those who had previous abdominal 
surgeries because these patients are more likely to have pelvic adhesions and thereby sustain 
more radiotherapy complications. Terminal ileum is the most common site to be involved 
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because of its fixity at cecum. Patients have abdominal cramps, diarrhea and distension. Fever 
and anemia may be present. These patients should be treated with total parenteral nutrition, 
nasogastric suction and early surgical intervention. 
Bladder complications 
 Vesicovaginal fistula is the most common complications and it requires supravesical 
urinary diversion. Small fistula can be repaired with omental pedicle or bulbocavernous flap. 
Ureteral stricture can occur either due to radiation fibrosis or recurrent cancer. Before surgical 
correction of stricture, biopsy from the site of obstruction and CT scan should be done to rule out 
recurrence of the disease. Ureterolysis or stents are used to relieve the obstruction. 
Neoadjuvant chemotherapy 
 Neoadjuvant chemotherapy followed by surgery is one of the treatment options in early 
stage cervical cancer. Sardis et al in his randomized trial, the control arm (75 patients) underwent 
Wertheim’s radical surgery followed by adjuvant radiation whereas in neoadjuvant group (76 
patients) radical surgery was preceded by three cycles of VBP regimen (vincristine, bleomycin 
and cisplatin). Survival and progression free survival was improved in neoadjuvant group 
because of decrease in incidence of loco-regional recurrence.(83). Pelvic recurrences were found 
in 23% of patients in control arm compared with 8% in the neoadjuvant group. 
 Recent Cochrane database systematic review assessed the role of neoadjuvant 
chemotherapy in patients with early stage or locally advanced cervical carcinoma found that 
significant improvement in overall survival and progression free survival with neoadjuvant 
chemotherapy.(84). These results indicate that neoadjuvant chemotherapy may offer benefit over 
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surgery alone for patients with early or locally advanced cervical carcinoma and these evidence 
is based on small number of trials and further research is warranted to confirm the benefits of 
neoadjuvant chemotherapy. 
Radiation and Extrafascial Hysterectomy 
 Durrance et al reported in his series that central failure could be reduced from 15% to 3% 
by addition of extrafascial hysterectomy after primary radiotherapy. For patients with bulky 
endocervical squamous cell carcinomas or adenocarcinomas, treatment with radiation therapy 
will achieve local control and survival rates are comparable to treatment with radiation therapy 
plus hysterectomy. Surgery after radiation therapy may be indicated for some patients with 
tumors confined to the cervix which respond incompletely to radiation therapy or in whom 
vaginal anatomy precludes optimal brachytherapy. 
 Combination radiotherapy and surgery is the treatment option in patients with barrel 
shaped cervix. An extrafascial hysterectomy is done 2 to 3 months after completion of 
radiotherapy to resect the central persistent tumor. This method results in lower rate of central 
failure (2%) and it is not clear whether it improves the overall survival rate. GOG performed a 
randomized trial to evaluate the role of adjuvant hysterectomy after radiation in improving the 
overall survival and progression free survival in patients with bulky IB cervical cancer. There 
was lower incidence of local relapse however there were no statistical difference in overall and 
progression free survival in the radiation and hysterectomy group. So they concluded that overall 
there was no important benefit with the use of extrafascial hysterectomy.(85). 
 
 57 
 
Post treatment surveillance 
 The patients should be monitored once in 3 months for first 2 years, every 6 months for 3 
years and then yearly thereafter. At each visit, physical examination, abdominal examination and 
rectovaginal examination should be done to detect the recurrence of disease. Pap smear should 
be done in every visit. Radiological examination is not routinely required unless patient has 
recurrence of disease. Chest X-ray should be done yearly to rule out pulmonary metastasis. PET 
scan is a sensitive tool for detection of recurrence in patients who has clinical features suspicious 
of recurrence. 
Prognosis  
5 year survival rate according to FIGO stage is given below,(86) 
  Stage IA - 95 - 100%  
  Stage IB - 80 - 85% 
  Stage IIA - 60 - 65% 
  Stage IIB - 55 - 60% 
  Stage IIIA - 30 – 35% 
  Stage IIIB - 25 – 30% 
  Stage IV - 15 – 20% 
The 5 year survival rate of patients with early stage cervical carcinoma who had radical 
surgery is 80% which is almost equal to primary radiation therapy. Landoni et al in 1997 
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confirmed this finding in a randomized controlled trial. (87). There are various retrospective 
studies available in the literature to evaluate the 5 year survival outcome of patients who 
underwent radical surgery as primary therapy and they showed that the overall survival is 
approximately 85-90% with minimal recurrence and postoperative morbidity. 
Studies on survival outcome and morbidity following radical hysterectomy and pelvic 
lymphadenectomy in early stage cervical carcinoma: 
1. A study which was conducted in 1253 patients in Thailand to evaluate the outcome 
and complications of early stage cervical cancer treated with radical hysterectomy 
and pelvic lymphadenectomy showed 10 year recurrence free survival rate was 90%. 
Lymphedema was the most common complication in their study. (88). They 
concluded that early stage cervical cancer patients who had radical surgery have 
favorable outcome with minimal morbidity. 
2. A retrospective study evaluated the effect of type II radical hysterectomy alone or 
with adjuvant treatment in 960 patients with stage IB to IIB cervical cancer showed 
that the 5 year overall survival rate was between 80-90% with recurrence rate of 14%. 
They concluded that type II radical hysterectomy is a feasible option for stage IB to 
IIB cervical cancer patients.(89).  
3. A retrospective study was done to compare the outcome and complications following 
radical surgery with or without adjuvant RT in the treatment of IB1 and IB2 cervical 
cancer. 153 patients underwent radical surgery, 69 received adjuvant RT. The 5 year 
survival rate was 96% for surgery alone and 91% for surgery and RT. There was 
statistically significant difference in the complications in surgery alone group and 
surgery and RT (12% vs 32%). They concluded that in stage IB1 and IB2 cervical 
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cancer patients, radical surgery has better outcome with less severe 
complications.(90). 
4. A study was performed in Turkey to identify the pathological risk factors that could 
predict 5 year disease free survival in patients with stage I-II who underwent radical 
hysterectomy and pelvic and para aortic lymphadenectomy. This retrospective study 
included 93 patients. 5 year disease free survival was 87%.  LVSI, grade 2/3 of the 
tumour and parametrial involvement were the prognostic factors that independently 
affected survival.(91).  
5. Another retrospective study was performed to assess the 5 year survival rate and 
morbidity following Wertheim’s operation in early stage disease. This study included 
501 patients in 10 year period. The 5 year survival rate was 94%, 90%, 84% and 71% 
in stage IA1, IB1, IB2 and IIA respectively and they concluded that radical 
abdominal hysterectomy with pelvic lymph node dissection is the treatment of choice 
in early stage cervical carcinoma.(92). 
6. John et al conducted a retrospective study to evaluate the efficacy and safety of 
radical surgery in early stage cervical carcinoma. 40 patients underwent this radical 
surgery in 8 year period. Overall survival was 92%, 15% had lymph node metastasis. 
There was no operative mortality or fistulae. They concluded that with proper patient 
selection and good operative technique, the survival rate are good with minimal 
complications.(93). 
7. A study was conducted in India by Rajashekar et al to evaluate the outcome of radical 
surgery in patients with early stage cervical carcinoma which recruited 601 cases in 
10 year period. Patients were classified in to low risk, intermediate risk and high risk 
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groups and postoperative adjuvant therapy was given to the patients with high risk 
groups. The 5 year disease free survival was 85% in low risk, 70% in intermediate 
and 60% in high risk group. They concluded that risk based adjuvant therapy provides 
better outcome, about 11%  improvement in survival.(94). 
8. Bezerra et al conducted a retrospective study in Brazil to evaluate the prognostic 
factors associated with recurrence and survival in stage I-IIA patients who underwent 
radical hysterectomy. 5 year survival rate was 85% and recurrence rate was 9%. 
Postoperative wound infections were 6% and bladder dysfunction was 3%. (95). 
These studies finally concluded that radical surgery has better survival rates with minimal 
complications with proper case selection and excellent operative techniques. These are all 
retrospective studies and there is no prospective studies conducted in this field to evaluate the 
outcome of the radical surgery. 
Very few studies were conducted in India to evaluate the survival outcome and 
complications of radical hysterectomy and pelvic lymphadenectomy. 
1. In Mitra’s series, 391 patients with cervical carcinoma had Radical vaginal 
hysterectomy and pelvic lymphadenectomy followed by radiotherapy and the 5 year 
survival rate was 67% for stage I and 47% for stage II disease. 15 patients had 
bladder injury, 7 had rectal injury, 3 had VVF and RVF and 1 patient had ureteral 
fistula. 
2. A retrospective study was conducted in AIIMS, New Delhi which compared the 
outcome of postoperative RT following inadvertent simple Hysterectomy and Radical 
Hysterectomy in cervical cancer. Local control of disease with simple versus radical 
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hysterectomy was 70% and 88% respectively and 5 year survival rate was 62%. 
Progression free survival was better in radical hysterectomy group (72% vs 49%). 
However surgical complications were also higher in radical hysterectomy group.  
They concluded that postoperative RT provides better clinical benefit in patients who 
had undergone radical hysterectomy for early stage cervical carcinoma.  
3. Another study compared the laparoscopic radical vaginal hysterectomy with open 
radical hysterectomy for early stage cervical cancer showed that intra-operative blood 
loss and hospital stay were less in laparoscopic surgery. The 2 year overall survival 
rate was 94% in both groups and intra operative complications were higher in 
laparoscopy group (13% vs 4%). The complications were one ureteral and bowel 
injury and 7 cystotomies. Recurrences were higher in laparotomy group (13% vs 4%). 
They concluded that laparoscopic radical surgery is associated with more intra 
operative complications and increase time to return to normal bladder function.      
These are the studies available in India in cervical cancer however none of the studies 
evaluated the survival outcomes, surgical complications and prognostic factors for recurrence in 
patients with early stage cervical cancer who underwent radical abdominal hysterectomy and 
pelvic lymphadenectomy as primary therapy. There is no systematic review or metaanalysis done 
in this particular aspect hence we planned to conduct this study to evaluate the outcome of our 
patients who underwent this radical surgery in our institution.  
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     MATERIALS AND METHODS 
This study was approved by the Research Committee and Institutional Review Board 
(Ethics Committee) of Christian Medical College, Vellore.  
Settings: 
  This study was carried out in the Department of Obstetrics and Gynecology, Christian 
Medical College, Vellore. Patients with FIGO stage IA-IIA cervical carcinoma who had 
undergone Radical Hysterectomy and pelvic lymphadenectomy over 10 years from January 2001 
to December 2010 in our institution were recruited for this study. The list of patients who 
underwent this radical surgery was collected from the operation register and Medical records 
department. The treatment details and complications were collected by reviewing the OP charts 
and the data available in the computer.  
Inclusion criteria: 
 Patients with histologically confirmed FIGO stage IA-IIA cervical carcinoma who 
underwent radical hysterectomy (Type II or Type III) with pelvic lymphadenectomy as primary 
therapy. 
Exclusion criteria: 
 Patients with early stage cervical carcinoma who received chemotherapy or radiotherapy 
before surgery. 
Primary outcome: 
 5 year survival rate of patients who underwent radical surgery. 
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Secondary outcome: 
 Progression free survival 
 Treatment related complications 
 Recurrence of disease after surgery 
 Requirement of adjuvant therapy 
 Risk factors for recurrence and death   
Sample size: 
 With 90% expected survival probability and with 95% confidential interval with 7.5% 
precision, the required sample size is 64. I included all patients with early stage cervical 
carcinoma who underwent radical surgery from January 2001 to December 2010. 
These patients were contacted by mail and over phone and asked them to come for 
review. When they came for review, I explained about the purpose of my study and I got consent 
from them. I took detailed history about their past treatment and present problems and clinical 
examination was done to look for local recurrence of the disease. USG abdomen & pelvis and 
chest X-ray was done to look for distant metastasis. 
Statistical analysis: 
 Statistical analysis of the data was carried out by the SPSS version 14.0 statistical 
software for window. Survival rate and progression free survival rate were analyzed using 
Kaplan-Meier life table analysis. Chi-square test was used for statistical analysis for significance 
wherever appropriate. Analysis of survival outcome and pattern of recurrence in various sub 
groups was done by using Log rank test. 
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       RESULTS  
The total number of patients with early stage cervical carcinoma who underwent Radical 
hysterectomy and pelvic lymphadenectomy from January 2001 to December 2010 were 61 
patients. 
Table 6:    Year of surgery 
Year of surgery Number of patients 
2001 2 
2002 6 
2003 4 
2004 1 
2005 5 
2006 8 
2007 16 
2008 9 
2009 6 
2010 4 
Total 61 
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Table 7:      Place distribution 
Place Number of patients Percentage (%) 
Vellore 26 42.6 
Rest of Tamil Nadu 15 24.5 
Andhra Pradesh 3 4.9 
West Bengal 8 13.1 
Rest of India 8 13.1 
Outside India 1 1.6 
Total 61 100 
 
Figure 2:   Place Distribution 
 
Most patients were from Vellore only (43%). 
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Table 8:        Baseline characteristics of the patients 
Variables Mean ± SD Average 
Age (years) 53 ± 10 (33 - 77) 
BMI (kg/m²) 26 ± 3.7 (19 – 33) 
Age at marriage 17 ± 3.5 (13 – 25) 
 
Table 9:     Parity of patients with carcinoma cervix 
Parity Number of patients Percentage (%) 
1 2 3.3 
2 16 26.2 
3 15 24.6 
4 17 27.9 
≥ 5 11 18 
 
3% of women were primiparous and 70% were multiparous having more than 3 children. 
Table 10:  HIV status of the patient 
HIV status N % 
Positive 0 0 
negative 61 100 
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Table 11:      HBs Ag status of the patient 
HBs Ag status N % 
Positive 2 3.3 
Negative 59 96.7 
 
Table 12:     VDRL status of the patient 
VDRL N % 
Positive 0 0 
Negative 5 8.2 
Not done 56 91.8 
 
During preoperative workup, 100% were HIV negative, 3.3% were found to be HBs Ag 
positive and in 92% of patients VDRL test was not done. Only 5 patients had VDRL testing and 
none of them had positive result. 
Table 13:     ASA grading of patients who had radical surgery 
ASA grade N % 
I 47 77 
II 14 23 
III 0 0 
IV and V 0 0 
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Those who had radical surgery, 77% were belonging to ASA grade 1 and 23% belong to 
ASA grade II category. 
 
Table 14 :         Patients who had pap smear testing 
  
Pap smear n % 
Koilocytic 0 0 
ASCUS/ Atypical cells 15 24.5 
Mild dysplasia 0 0 
Moderate dysplasia 2 3.3 
Severe dysplasia 4 6.6 
Malignancy 0 0 
Not done 35 57 
Negative 5 8 
 
35 patients did not have Pap smear examination because of obvious growth and 
remaining patients had Pap smear test which was done in 6 months to 1 year before surgery. 
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Table 15 :     FIGO stage of patients with carcinoma cervix 
Stage  n % 
IA1 2 3.2 
IA2 5 8.2 
IB1 44 72 
IB2 5 8.2 
IIA 5 8.2 
 
During the ten year period, radical surgery was performed in 44 patients (72%) with stage 
IB1 whereas other stages comprised only 8%. 2 patients were in stage IA1 with LVSI positive 
hence they underwent radical hysterectomy. 
 
Figure 3:       FIGO stage of the patient 
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Table 16 :     Pathological type of tumor in patients with Carcinoma cervix 
Pathological type n % 
Squamous cell carcinoma 48 78.7 
Adenocarcinoma 11 18 
Adenosquamous carcinoma 1 1.6 
Neuroendocrine tumour 0 0 
Papillary serous carcinoma 0 0 
Others 1 1.6 
 
Squamous cell carcinoma was the most common histological type accounting for 78.7% 
followed by adenocarcinoma accounting for 18% and 1 patient had adenosquamous carcinoma 
and 1 patient had pleomorphic rhabdomyosarcoma of cervix. 
Table 17:        Pathological subtypes of squamous cell carcinoma (SCC) 
SCC – sub types n % 
Large cell keratinizing SCC 27 56 
Large cell non-keratinizing SCC 6 12.5 
Small cell carcinoma 1 2 
Not specified 14 29 
 
Among 48 patients with squamous cell carcinoma, large cell keratinizing SCC accounting for 
56% and large cell non-keratinizing SCC accounting for 13% and small cell carcinoma for 2%. 
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Figure 4:        Pathological subtypes of squamous cell carcinoma 
Table 18:       Grade of the tumour 
Grade n % 
G1 2 3.2 
G2 44 72.1 
G3 5 8.2 
Not specified 10 1.6 
 
The percentage of grade 1, 2 and 3 are 3%, 72%, 8% respectively. The most common 
grade was grade 2 in patients with carcinoma cervix. 
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Table 19:      Size of the tumour 
Tumour size n % 
< 4cm 51 84 
> 4cm 10 16 
 
The maximum size of the tumour was < 4cm (84%). 
Table 20:        Pathological risk factors 
Pathological risk factors positive % 
Margins 12 19.7  
LVSI 15 24.6 
Deep stromal invasion 24 39.3 
Parametrial invasion 4 6.5 
Pelvic lymph node metastasis 9 14.7 
 
High risk factors for recurrence like pelvic lymph nodes, parametrial and positive vaginal 
margin were detected in 14.7%, 6.5% and 19.7% of the patients respectively. Mean number of 
pelvic lymph node removed was 12. 
Surgical complications: 
 The surgical complications were divided in to intra-operative, immediate and post-
operative complications. 
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Table 21:    Intra-operative complications 
Complications  No of patient  % 
< 1500ml blood loss 57 93.4 
> 1500ml blood loss 4 6.6 
Blood transfusion 20 32.8 
Bladder injury 0 0 
Bowel injury 1 1.6 
Ureter injury 3 4.9 
Pelvic vessel injury 3 4.9 
 
Blood loss was not much in our patients who underwent radical surgery and only 4 
patients had more than 1500ml blood loss and remaining 57 patients had less than 1500ml blood 
loss. Only 33% of patients received blood transfusion. Intra-operative complications occurred in 
7 patients (11.4%) which included injury to the bowel (1.6%), ureter (4.9%) and pelvic vessels 
(4.9%). 
Immediate postoperative complications 
UTI was the most common immediate postoperative complication (30%) followed by 
voiding dysfunction in 23% of patients which required prolonged continuous bladder drainage. 
Wound dehiscence occurred in 10% of patients and required resuturing. One patient had uretero-
vaginal fistula and she underwent DJ stenting. 
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Table 22 :      Immediate postoperative complications 
Complications  
No. of patients 
(n=61) 
% 
UTI 18 30% 
Ureteral fistula 1 1.6 
Rectal fistula 0 0 
Vesical fistula 0 0 
Wound dehiscence 6 9.8 
Thromboembolism 1 1.6 
Voiding dysfunction 14 23 
Lymphocyst 0 0 
Respiratory tract infections 0 0 
  
Table 23:     Late postoperative complications  
Complications 
No of patients 
(N=54) 
% 
Ureteric stenosis 1 1.8 
Lymphedema 1 1.8 
Bladder dysfunction 2 3.7 
Bowel complications 2 3.7 
Death within 1 month 0 0 
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7 patients did not come after surgery hence late complications were calculated from 54 
patients. Ureteric stenosis and lymphedema occurred in one patient (1.8%). 2 patients developed 
bladder dysfunction out of which one patient received adjuvant radiotherapy and another patient 
had neurovesical bladder dysfunction. This patient did not receive any adjuvant RT and she was 
on continuous intermittent self-catheterization and anticholinergics. 2 patients had bowel 
complications and both of them received adjuvant RT. 
Table 24:              Postoperative adjuvant therapy (n=54) 
Adjuvant therapy n % 
Radiotherapy 22 41 
Chemotherapy 0 0 
Chemoradiation  0 0 
Hormonal therapy 0 0 
Palliation  1 1.9  
 
22 patients received adjuvant radiotherapy in view of presence of intermittent and high 
risk factors for recurrence. 2 patients received only brachytherapy and 1 patient received only 
external beam therapy. Remaining 19 patients received both external beam therapy and 
brachytherapy.  Palliative treatment was received by one patient who had ureterovaginal fistula 
in the postoperative period and she underwent DJ stenting.  32 patients did not require any 
adjuvant therapy (59%). 
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Figure 5:   Adjuvant therapy in patients with CA cervix. 
Table 25:         Adjuvant RT according to prognostic factors 
Prognostic factors 
No of patients 
(n=22) 
Intermediate risk factors 8  
High risk factors 14 
 
Among 22 patients who received adjuvant RT, 8 patients had intermediate risk factors and 14 
had high risk factors. 
 Recurrence of the disease 
Among 61 patients, 7 patients did come for follow up after surgery. 8 patients (15%) 
developed recurrence of disease out of 54 patients. 
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Table 26:        Recurrence of disease 
           Variable  n % 
Recurrence of disease 
          Local recurrence 
          Distal recurrence 
8 
7 
1 
15 
88 
12 
 
Among 8 patients, 88% developed local (vault) recurrence and 12% developed distant 
metastasis i.e. metastasis in the lung and para-iliac nodes. She received palliative RT for distant 
metastasis. 
5 year survival rate:  
 It is the percentage of people who are alive at 5 years after being diagnosed or treated for 
the disease or cancer. It is calculated from the date of surgery to patients who are alive at 36, 60 
and 120 months. 
Table 27:     Survival rate at 3, 5 and 10 years 
Time Estimate (%) 95%  conf. Interval 
36 months (3 years) 98% 86-99 
60 months (5years) 95% 82-98 
120 months (10 years) 83% 44-96 
 
Out of 61 patients, 54 were on regular follow up and 7 patients did not come after 
surgery. Out of these 54 patients, 37 were alive and they came for review. 3 patients expired. 
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Hence survival outcome is calculated from these 54 patients. The overall 5 year survival rate is 
95% and 10 year rate is 83%. The survival rate is described in the following Kaplan-Meier curve. 
Figure 6:    Kaplan-Meier survival curve indicating 3, 5 and 10 year survival rate 
 
 
Table 28:         Patients who came for follow up at 3, 5 and 10 years 
Months No of patients Cumulative % 
36 22 36 
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 61-120 28 46 
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Figure 7:      Kaplan – Meier curve for overall 5 year survival rate 
 
Figure 8:       Survival outcome according to FIGO stage    
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Survival outcome according to FIGO stage IA1, IA2 and IB1 are shown in the figure. 
Stage IB2 and IIA are not included because they had very less patients. 
Table 29:    5 year survival rate according to FIGO stage in our study 
FIGO stage 
No. of patients survived 
more than 5 years 
Percent 
IA1 2 100 
IA2 4 80 
IB1 27 71 
IB2 1 25 
IIA 1 20 
 
FIGO stage IA1 had better survival rate followed by IA2 and IB1. (P = 0.55). Stage IB2 
and IIA had survival rate of 25% and 20% respectively. 
Survival analysis according to pathological type of cervical carcinoma 
Table 30: 
Pathological type No of patients survived 5 year survival rate 
Squamous cell carcinoma 26/48 54% 
Adenocarcinoma 8/11 73% 
  
 In our study adenocarcinoma had better survival (73%) than squamous cell carcinoma 
(54%) but this is not statistically significant. (p value is 0.5) 
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Figure 9:  Survival curve according to pathological type of cervical cancer 
 In this figure, pathological type 1 indicates squamous cell carcinoma and type 2 indicates 
adenocarcinoma. 
 
Survival analysis in subgroups 
Table 31:    5 year Survival rate according to intermediate risk factors  
Risk factors No of patients survived 5 year survival rate 
Larger size of tumour 1 / 7 14% 
Deep stromal invasion 12 / 22 55% 
LVSI 8 / 13 62% 
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Table 32:    5 year survival rate according to high risk factors 
Risk factors 
No of patients survived 
after 5 years 
5 year survival rate 
Positive margins 6 / 10 60% 
Parametrial invasion nil - 
Positive lymph nodes 5 / 9 56% 
 
 5 year survival rate is almost similar in patients with intermediate risk factors and high 
risk factors.  
Table  33:   5 year survival rate according to lymph node status. 
Pelvic lymphnodes n 5 year survival rate 
Positive lymphnodes 5 / 9 56% 
Negative lymphnodes 29 / 45 64% 
 
Patients with lymph node metastasis had less 5 year survival rate (56%) than with 
negative lymph nodes (64%) however this is not statistically significant. (p - 0.7). 
 Progression free survival: 
 It is defined as length of time during and after treatment for cancer that a patient lives 
with the disease but it does not get worse. 
Progression free survival rate at 3, 5 and 10 years is mentioned in the table. 
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Table  34: 
Time (months) Percent 95% CI 
36 92% 80-96 
60 81% 66-90 
120 81% 66-90 
 
Recurrence occurred in 8% of patients within 36 months and 19% by 60 months.  
Recurrence of disease in various sub groups: 
 8 patients developed recurrence of disease in our study (15%). 
Table 35:     Site of recurrence in relation to adjuvant radiotherapy    
Mode of treatment n Recurrence Local recurrence Distant recurrence 
Surgery and RT 22 3 (14%) 3 0 
Surgery alone 32 5 (16%) 4 1 
Total 54 8 7 1 
 
 From this table we can see that patients who had adjuvant RT had low recurrence (14%) 
than who had surgery alone (16%) however this is not statistically significant. (p value is 1.0). 
Hence adjuvant radiotherapy decreases the incidence of recurrence of the disease and there by 
improves the survival of the patient. 
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Distribution of intermediate risk factors among patients who developed tumour recurrence 
Table 36: 
 
Prognostic factors 
Recurrence of disease  
P value  Present Absent 
Size > 4cm 3 (43%) 4 (57%) 0.06 
Deep stromal invasion 2 (10%)  19 (90%) 0.6 
LVSI 1 (8%) 11 (92%) 0.3 
  
Table 37:   Distribution of high risk factors among patients who developed tumour recurrence 
Prognostic factors 
Recurrence of disease  
P value  Present Absent 
Positive margins 3 (30%) 7 (70%) 0.17 
Parametrial invasion 2 (50%) 2 (50%) 0.1 
Positive lymph nodes 1 (11%) 8 (89%) 1.0 
 
Out of 8 patients who had recurrence of disease, 6 patients had intermediate and high risk 
factors and remaining 2 patients had recurrence without having any risk factors. The status of 
deep stromal invasion of the surgical specimen was available for analysis in 52 patients. Of the 
21 patients with deep stromal invasion, 2 (10%) developed tumour recurrence whereas 5 out of 
26 (19%) who did not have stromal invasion had subsequent tumour recurrence (ρ value - 0.6). 
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LVSI was positive in 12 patients out of this, 1 (8%) developed tumor recurrence whereas 4 out of 
14 (29%) developed tumour recurrence without lymphovascular space invasion. (ρ value - 0.3). 
The distribution of high risk factors of recurrence like positive resection margin, 
parametrial invasion and lymph node metastasis were available in 52 patients. Of the 10 patients 
with positive margins, 3 (30%) developed tumour recurrence whereas 5 out of 42 (12%) patients 
whose resection margins were clear had subsequent tumour recurrence. (ρ value 0.17).  Likewise 
4 patients with parametrial invasion, 2 (50%) developed tumour recurrence whereas 6 out of 48 
(13%) whose parametrium were clear had subsequent tumour recurrence. (ρ value 0.1). 
Table  38:    Recurrence of disease according to lymph node status. 
Lymph node status 
Recurrence of disease 
Present Absent 
Positive lymph nodes 1 (11%) 8 (89%) 
Negative lymph nodes 7 (16%) 38 (84%) 
  
In our study, 9 patients had pelvic lymph node metastasis. Recurrence occurred in 1 
(11%) out of these 9 patients and 7 out of 45 patients (16%) had recurrence with negative lymph 
nodes. However this was not statistically significant (ρ value - 1.0). 
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DISCUSSION  
Cervical cancer is the second most common cancer among women in developing 
countries. India is one of the countries which has highest incidence of cervical cancer with poor 
survival rates. Till now, not many studies have been conducted in India to evaluate the outcome 
of radical hysterectomy in patients with early stage cervical cancer. However some retrospective 
studies have been conducted in western population. There is no systematic review done on 
outcome of radical hysterectomy in early stage cervical carcinoma. Hence we decided to conduct 
this study on our patients to evaluate the outcome of this surgery. 
There were 61 patients who underwent this radical surgery from 2001 to 2010. Out of 
these 61 patients, 7 patients did not come for follow up after surgery. Remaining 54 patients 
were on follow up but all of them were not on regular follow up and some of them have 
defaulted at various points in time. We contacted all 61 patients through mail and phone calls 
and 37 patients responded and came for review. 3 patients died due to the disease.  
Comparing the place distribution, 43% of patients were from local area in and around 
Vellore and 25% from rest of Tamil Nadu. 26% were from North India out of this, 13% from 
West Bengal.  The mean age of the patients in our study was 53 but ranged from 33 to 77 years. 
Mean BMI was 26 kg/m2 and mean age at marriage was 17 years. 3% of patients were primi-
parous and the incidence of cervical cancer was 10 fold high in women with high parity (≥ 4).  
During preoperative evaluation, 100% were HIV negative and 3% were found to be HBs 
Ag positive. 77% patients belong to ASA grade I and 23% were ASA grade II. Out of 61 
patients, 3% of patients were FIGO stage IA1, 8% were stage IA2 and 72% were IB1. Stage IB2 
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and IIA were both 8% each. 2 patients with stage IA1 patients underwent radical surgery because 
of lymphovascular space invasion. 
In our study most common pathological type was squamous cell carcinoma 79% and 
adenocarcinoma 18% and one patient had adenosquamous carcinoma. Our report is comparable 
to Hopkins et al study.(16). One patient had very rare variety of carcinoma, pleomorphic 
rhabdomyosarcoma of cervix. Among squamous cell carcinoma, large cell keratinizing SCC 
accounted for 56%, large cell non-keratinizing SCC accounted for 13% and small cell carcinoma 
for 2%.  
The most common grade of the tumour was grade 2 accounting for almost 70% and grade 
1 and grade 3 tumours were 3% and 8% respectively. The maximum size of the tumor was less 
than 4 cm (84%). All 61 patients underwent radical hysterectomy followed by pelvic 
lymphadenectomy and only one patient had para-aortic lymphadenectomy as well. The 
intermediate risk factors for recurrence like larger tumour size, deep stromal invasion and LVSI 
were found in 16%, 39% and 25% respectively. High risk factors for recurrence like positive 
margins and parametrial invasion were found in 20% and 7% respectively. Metastasis of pelvic 
lymph nodes was found in 15% of patients. This is comparable to the report by Powell et al.  The 
mean number of removal pelvic lymph nodes was 12 (range 4 – 25).  
The overall survival rate of our patients was 98% at 3 years, 95% at 5 years and 83% at 
10 years. These results were comparable to recent reports by Powell et al (93) with an overall 5 
year survival rate of 92.5%. In our study FIGO stage IA1 had better 5 year survival rate (100%) 
followed by IA2 (80%) and IB1 (71%). Stage IB2 and IIA had survival rate of 25% and 20% 
respectively.  
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Interestingly, our patients with adenocarcinoma of cervix appeared to have better survival 
rate (73%) than squamous cell carcinoma (54%) but this is not statistically significant (ρ - 0.5). 
And none of the patients with adenocarcinoma had recurrence of tumour. All recurrences occur 
in patients with high grade squamous cell carcinoma who had intermediate and high risk factors 
for recurrence. This is in marked contrast to the available literature reports. Eifel et al found a 
recurrence rate of  45% in their series of adenocarcinoma of cervix.(17). However our study 
showed no recurrence in patients with adenocarcinoma of cervix which is consistent with that 
reported by Tay and Tan et al. Hence our results concurred with the conclusion of Steren et al 
that radical surgery is an acceptable primary modality of treatment for early stage 
adenocarcinoma of the cervix.  
In our study, patients without stromal invasion had survival rate of 67% which dropped 
down to 55% with deep stromal invasion. The survival rates were similar for patients with or 
without tumour embolisation of lymphovascular channels. This was also true for patients with 
positive or negative resected margin. Lymph node status is the important factor which predicts 
the 5 year survival rate. The survival rate in patients with negative nodes is 64% and 56% with 
positive lymph nodes. However this is not statistically significant.  
Progression free survival was 92% at 3 years and 81% at 5 years. 15% of patients 
developed recurrence in our study.  Out of this, 88% were local recurrences and 12% were extra 
pelvic recurrences. These results are comparable to recent reports by Min Zheng et al with an 
overall recurrence rate of  14%.(89). Among 8 patients with tumour recurrence, 6 patients had 
intermediate risk factors. Among these 6 patients, 3 patients had larger tumour size, 2 patients 
had deep stromal invasion and 1 patient had positive LVSI.  The recurrence rate was 10% in 
patients with deep stromal invasion compared to 19% of patients without stromal invasion but 
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this is not statistically significant. (ρ value - 0.6). The recurrence rate was 8% with LVSI positive 
compared to 29% without lymphovascular space invasion but this is not statistically significant. 
(ρ value - 0.3).  
6 patients who developed tumour recurrence had high risk factors, out of this 3 patients 
had positive margins, 2 patients had parametrial invasion and 1 had metastasis to pelvic lymph 
nodes. The recurrence rate was 30% in patients with involved resection margins compared to 
12% with clear margins. Similar result (36% vs 9%) was reported by McCann et al.(96). The 
recurrence rate was 50% with parametrial invasion compared to 13% with absent parametrial 
invasion. 
Lymphnode metastasis is the strongest risk factor predicting the recurrence of the disease. 
Among 8 patients who had recurrence in our study, 11% of patients with positive lymph nodes 
had recurrence whereas 16% had recurrence with negative lymph nodes. This result is similar to 
that reported by Pedulla et al. The reason for lower rate of recurrence in positive nodes may be 
the consequence of thorough lymphadenectomy and postoperative adjuvant radiotherapy. 
In our study, 41% received adjuvant RT in form of external beam therapy and vaginal 
brachytherapy. 59% did not receive any adjuvant therapy. Among patients who received 
adjuvant radiotherapy, 14% of patients had local (vault) recurrence but there was no distant 
recurrence. However in patients who had surgery alone without adjuvant RT, the recurrence rate 
was 16%. Of this non-irradiated group, 80% were local recurrences and 20% were distant 
recurrence. Hence postoperative adjuvant radiotherapy improved the pelvic control of the 
disease. But there was no significant improvement in overall 5 year survival among the 
postoperatively irradiated patients in our study.  
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  Radical hysterectomy is associated with serious morbidities. In our study, the most 
common intra-operative complication was blood loss which was less than 1500ml. only 7% of 
patients had blood loss more than 1500ml and 33% of our patients received blood transfusions. 1 
patient had bowel injury (sigmoid colon) and required repair & colostomy. 3 patients (4.9%) had 
ureter injury and they underwent repair and stenting. 3 patients (4.9%) had pelvic vessel injury. 
Ureteric injury was slightly higher in our study compared to 1.5% occurred in the study 
conducted by Pikart et al.  
 UTI was the most common immediate postoperative complication (30%) followed by 
voiding dysfunction in 23% of patients which required prolonged continuous bladder drainage. 
Wound dehiscence occurred in 10% of patients which was similar to report by Zorlu et al.           
1 patient (1.6%) had DVT in the postoperative period and 1 patient (1.6%) had ureterovaginal 
fistula and she underwent DJ stenting. All these complications were slightly higher when 
compared to the report by Wu et al(97) in which the complications were bladder 
dysfunction(10%), wound infection(7%) and ureteral fistula(0.5%). None of our patients 
developed lymphocyst and immediate postoperative mortality. 
The chronic complications in our patients were bladder dysfunction and bowel 
complications which occurred at a rate of 3.7% each. In our study, 2.1% of patients had 
lymphedema which is similar to the recent report by Manchana et al.(64). In his series, the long 
term complications were bladder complications and lymphedema which occurred at a rate of 
1.4% and 2.1% respectively. 
     
 
 91 
 
LIMITATIONS  
Though this observational study analyzed data of all patients diagnosed as carcinoma 
cervix who underwent radical surgery in our hospital during a 10 year period from 2001 to 2010, 
the major limitation of our study is patients who are lost to follow up after surgery. The 
important reasons are lack of awareness regarding the disease condition, the need for regular 
follow up and financial constraints. In our country, illiteracy and poverty play a contributory  
role to the above factors. 
Another drawback of this study is inability to contact many patients and get information 
regarding their present health status. The reason for the above limitation are the incorrect and 
incomplete contact addresses and phone numbers of the patients available in the medical records 
and due to migration of the patients and failure to update their new contact information with the 
hospital’s database. Also some charts could not be traced from the medical records department 
and some charts had incomplete documentation of the patient’s disease condition thus 
contributing to the bias noted in our study. 
In view of the various above mentioned limiting factors, we could not evaluate the 
survival outcome of all the patients included in our study. 
 
 
 
 
 92 
 
 
SUGGESTIONS  
In order to overcome all these barriers, we suggest that a cancer registry should be 
maintained in our department. There should be electronic data entry of all information about the 
patient, their contact address, phone numbers, their disease status, treatment details and follow 
up visits etc. A health worker should be assigned for this purpose and they should make frequent 
calls or home visits to the patients who are not coming for regular follow up. Records of death of 
the patient, cause of death and its details should also be maintained.  
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CONCLUSIONS 
1. The 5 year survival rate of patients with early stage cervical carcinoma who underwent 
Radical hysterectomy in our institution was 95%. 
2. Recurrence occurred in 8% of patients within 36 months and 19% by 60 months. 
3. Intra-operative complications were seen in 11% ; the main ones being 4.9% ureteric 
injury, 4.9% injury to pelvic vessels and 1.6% bowel injury. In the post-operative period, 
30% of patients had urinary tract infections, 23% developed voiding dysfunction, 10% 
had wound dehiscence and 1.6% had ureteric fistula. Late complications included 3.7% 
bladder dysfunction, 3.7% had bowel complications and 1.8% lymphedema. 
4.  The incidence of recurrence of disease after radical surgery in our study was 15%. Out of 
which, 88% of patients had local (vault) recurrence and 12% had distant metastasis. 
Though our study did not find any statistically significant independent risk factors for 
recurrence in patients with early stage cervical carcinoma, high grade squamous cell 
carcinoma histology, positive margins and parametrial invasion were found to correlate 
with higher incidence of recurrence in such patients. 
5. Adjuvant radiotherapy was given in 41% of patients due to presence of intermediate and 
high risk factors. Patients who received adjuvant RT had low incidence of recurrence of 
disease than those who did not receive adjuvant RT however this was not statistically 
significant.  
6. With proper selection of patients and with good operative technique, the survival rates are 
good with minimal complications in patients with early stage cervical cancer treated by 
Radical hysterectomy and pelvic lymphadenectomy.  
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ANNEXURES  
ANNEXURE I  -   ABBREVIATIONS 
CIN        Cervical Intraepithelial Neoplasia 
HPV        Human papilloma virus 
LVSI        Lymphovascular space invasion 
LARVH  Laparoscopic assisted Radical Vaginal Hysterectomy 
GOG  Gynecology oncology group 
5 FU  5 Fluorouracil 
BMI  Body mass Index 
VVF  Vesico-vaginal Fistula 
RVF  Recto-vaginal Fistula 
FIGO  International Federation of Obstetrics and Gynecology 
ASA  American Society of anesthesiology 
SCC  Squamous cell carcinoma 
MRI  Magnetic Resonance Imaging 
PET  Positron Emission Tomography 
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      ANNEXURE II 
               INFORMED   CONSENT 
                     Participant information sheet 
Study on surgical outcomes of early stage cervical carcinoma treated with Radical 
Hysterectomy & Pelvic lymphadenectomy in CMC. 
You are being requested to participate in this study to evaluate the outcome in terms of 
survival rate and surgical complications in patients who underwent Radical Hysterectomy & 
pelvic lymphadenectomy for early stage cervical cancer. We have planned to include all patients 
who underwent this surgery between Jan 2001 – Dec 2010 
What is the need for the study? 
Cervical cancer is the most common gynecological cancer in India and other developing 
countries. Standard treatment of early stage cervical cancer includes either Radical hysterectomy 
& pelvic lymphadenectomy or radiation therapy which has been accepted as equally effective in 
terms of survival & local control of the disease. Surgical management of cervical cancer by 
Radical hysterectomy & pelvic lymphadenectomy has been proven a highly effective method in 
treating early stage disease. Studies have proved that with proper case selection and excellent 
operative techniques the survival rates are 90% with minimal complications. Even in our hospital 
many women underwent this radical surgery as a treatment for early stage cervical cancer. 
However the efficacy and safety of this surgery is yet to be studied. If you are part of this study 
and its survival outcomes are proven it will benefit other woman and it will also help us to decide 
which patients should be offered to this radical surgery. 
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Is there harm to you in participating in the study? 
There will be no harm to you during participation in the study.  The standard routine care 
will be continued independent of the study result. 
If you take part what will you have to do? 
If you agree to participate in this study you will be contacted by mail and will be asked to 
come for a review once. We will examine you and will do USG scan and chest X-ray. No 
additional procedures will be conducted for this study.  
Can you withdraw from this study after it starts? 
Your participation in this study is entirely voluntary and you are also free to decide to 
withdraw permission to participate in this study. If you do so, this will not affect your usual 
treatment at this hospital in any way. 
Will you have to pay for the study?  
NO payment is required for the study. The postal charges will be paid by us. The 
ultrasound scan and X-ray chest will be done free of cost. Any other treatment that you usually 
take will continue and the routine charges for the treatment will be paid by you.   
Will your personal details be kept confidential? 
The results of this study will be published in a medical journal but you will not be 
identified by name in any publication or presentation of results. However, your medical notes 
may be reviewed by people associated with the study, without your additional permission, should 
you decide to participate in this study. 
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If you have any further questions, please contact Dr. Angeline Gnanamalar or Dr. Rachel 
Chandy M.D., D.G.O (Ph.No  9840973325)  or  email  to og1@cmcvellore.ac.in 
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Format of Informed Consent form for Subjects  
Informed Consent form to participate in a research study  
Study Title:  Outcome of early stage cervical carcinoma treated with Radical hysterectomy and 
Pelvic lymphadenectomy 
Study Number: 
Subject’s Initials: _________ Subject’s Name: ________ 
Date of Birth / Age:_______  
I_____________________________________________________________ 
___________, wife  of  ___________________________________ 
Please tick boxes 
(i) I confirm that I have read and understood the information sheet dated _________ for the 
above study and have had the opportunity to ask questions. [ ] 
(ii) I understand that my participation in the study is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights being affected. [ ] 
 (iii) I understand that the Sponsor of the clinical trial, others working on the Sponsor’s behalf, 
the Ethics Committee and the regulatory authorities will not need my permission to look at my 
health records both in respect of the current study and any further research that may be 
conducted in relation to it, even if I withdraw from the trial. I agree to this access. However, I 
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understand that my identity will not be revealed in any information released to third parties or 
published. [ ] 
(iv) I agree not to restrict the use of any data or results that arise from this study provided such a 
use is only for scientific purpose(s) [ ] 
(v) I agree to take part in the above study. [ ] 
Signature (or Thumb impression) of the Subject/Legally Acceptable 
Representative:_____________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
 
Signature of the Witness: ___________________________ 
Date:_____/_____/_______ 
Name of the Witness: ______________________________ 
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ANNEXURE III 
GENERAL PROFORMA 
Outcome of Early Stage Cervical Carcinoma Treated With 
Radical Hysterectomy and Pelvic Lymphadenectomy  
                                                  
Study Participant Number : 
Name of the patient  : 
Hospital No.   : 
Age      : 
BMI     : 
Parity     : 
Age at marriage   : 
HIV status    : 1. Positive 2. Negative 3. Not done   
HBs Ag    : 1. Positive 2. Negative 3. Not done   
VDRL     : 1. Reactive  2. Non reactive  3. Not done   
Pap smear    : 1. Koilocytic  2. ASCUS/Atypical cells  
      3. Mild dysplasia  4. Moderate dysplasia 
      5. Severe dysplasia     6. Malignancy   
7. Not done  8. Negative  
ASA grade    :   1. I 2. II 3. III      
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FIGO stage    : 1. IA1  2.  IA2  3. IB1   
      4.  IB2  5.  IIA 
 
Pathological Type  :                 
1) Squamous cell carcinoma  -  subtypes: a. Large cell keratinizing           
        b. Large cell non-Keratinizing 
       c. Small cell  
       d. not specified 
2) Adeno carcinoma   -  
3) Adenosquamous carcinoma - 
4) Neuro endocrine carcinoma - 
5) Papillary serous   - 
6) Others      - 
Grade of Tumour   : 1. G1   2. G2     
      3. G3   4. Not specified 
Size of the Tumour  : 1. < 4 cm 2. > 4 cm   
Pathological risk factors : 
1) Margins     - 1. Positive 2. Negative 3. Not done  
2) LVSI     - 1. Positive 2. Negative 3. Not done  
3) Deep stromal invasion  - 1. Positive 2. Negative 3. Not done  
4) Parametrial extension  - 1. Yes  2. No  3. Not done  
5) Vaginal  extension   - 1. Yes  2. No  3. Not done ‘’ 
6) Pelvic lymph nodes total number -                                                                              
7) Number of positive lymph nodes -                    
  
Complications   : 
A. Intra operative complications  
1) Blood loss    - 1. < 1500 ml  2. > 1500 ml   
 110 
 
2) Blood transfusion (No. of  pints) -  1. 1 2. 2 3. >3 4. Nil   
3) Intra operative injury to adjacent organs  
a. Bladder   -  1. Yes  2. No  
b.  Bowel   -  1. Yes   2. No  
c. Ureter    -  1. Yes  2. No  
d. Pelvic vessels   -  1. Yes   2. No    
 
B. Immediate postoperative complications 
1) Urinary tract infections  - 1. Yes   2. No  
2) Fistula  
a. Ureteral   -  1. Yes   2. No  
b. Rectal    -  1. Yes   2. No  
c. Vesical   - 1. Yes   2. No  
3) Wound dehiscence   - 1. Yes   2. No  
4) Thromboembolism   - 1. Yes   2. No  
5) Voiding dysfunction   - 1. Yes   2. No  
6) Lymphocyst    -  1. Yes   2. No 
7) Bowel complications   - 1. Yes   2. No  
8) Respiratory tract infections - 1. Yes   2. No     
 
C. Late complications 
1) Ureteral stenosis   -  1. Yes   2. No  
2) Lymph edema   - 1. Yes   2. No   
3) Bladder dysfunction   - 1. Yes   2. No    
4) Death within 1 month  - 1. Yes   2. No   
5) Readmission    - 1. Yes   2. No      
 Adjuvant therapy  :  
 1) Radiotherapy     
     a. Brachytherapy                    
     b. External beam RT   
  c. Para aortic RT    
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  d. Brachytherapy & external beam RT 
  e. No RT                                      
2) Chemotherapy  -  1. Yes   2. No    
3) Chemoradiation  -    1. Yes   2. No  
4) Hormonal therapy  -   1. Yes   2. No  
           5) Palliation    -  1. Yes   2. No  
  
Recurrence of the Disease :  1. Yes  2. No   
Recurrence Date   :   
Site of recurrence  :  
1) Local (pelvic)    - 1. Yes   2. No  
2) Distant    - 1. Yes   2. No  
Concomitant Cancer  :  1. Yes    2. No  
Second malignancy  :  1. Yes   2. No  
Death    :  1. Yes    2. No   
 
Date of death   :    
Date of surgery   :       
Follow up till which year  : 
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